UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934.
For the quarterly period ended
Commission File Number:
(Exact name of Company as specified in its charter)
| ||
(State or other jurisdiction) |
| (IRS Employer Identification No.) |
of incorporation or organization) |
|
|
(Address of principal executive offices and zip code)
(
(Company’s telephone number, including area code)
Indicate by check mark whether the Company (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the Company was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Indicate by check mark whether the Company is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer | ☐ |
| Accelerated filer | ☐ |
☒ |
| Smaller reporting company | ||
| | Emerging growth company |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the Company is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes
Securities registered pursuant to Section 12(b) of the Act:
Title of each class: | | Trading Symbol(s) | | Name of each exchange on which registered: |
| | NYSE-American |
As of November 14, 2026 there were approximately
NanoViricides, Inc.
TABLE OF CONTENTS
2
PART I. FINANCIAL INFORMATION
Item 1. Financial Statements
NanoViricides, Inc.
Condensed Balance Sheets
| | | | | | |
| | September 30, | | June 30, | ||
| | 2026 | | 2026 | ||
| | (Unaudited) | | | | |
ASSETS | | | | | | |
CURRENT ASSETS: |
| | |
| | |
Cash and cash equivalents | | $ | | | $ | |
Prepaid expenses | | | | | | |
Total current assets | |
| | |
| |
| | | | | | |
Property and equipment, net | |
| | |
| |
| | | | | | |
Intangible assets, net | |
| | |
| |
| | | | | | |
OTHER ASSETS | |
| | |
| |
Service agreements | | | | | | |
Total assets | | $ | | | $ | |
| | | | | | |
LIABILITIES AND STOCKHOLDERS’ EQUITY | |
| | |
| |
CURRENT LIABILITIES: | |
| | |
| |
Accounts payable | | $ | | | $ | |
Accounts payable-related party | |
| | |
| |
Accrued expenses | |
| | |
| |
Accrued expenses-related party | | | | | | — |
Total current liabilities | |
| | |
| |
| | | | | | |
COMMITMENTS AND CONTINGENCIES (Note 10) | |
| | |
| |
| | | | | | |
STOCKHOLDERS’ EQUITY: | |
| | |
| |
Series A convertible preferred stock, $ | |
| | | | |
Common stock, $ | |
| | | | |
Additional paid-in capital | |
| | | | |
Accumulated deficit | |
| ( | | | ( |
| | | | | | |
Total stockholders’ equity | |
| | | | |
| | | | | | |
Total liabilities and stockholders’ equity | | $ | | | $ | |
See accompanying notes to the condensed financial statements
3
NanoViricides, Inc.
Condensed Statements of Operations
(Unaudited)
| | | | | | |
| | For the Three Months Ended | ||||
| | September 30, | ||||
| | 2026 | | 2025 | ||
OPERATING EXPENSES |
| | |
| | |
Research and development | | $ | | | $ | |
General and administrative | |
| | | | |
| | | | | | |
Total operating expenses | |
| | | | |
| | | | | | |
LOSS FROM OPERATIONS | |
| ( | | | ( |
| | | | | | |
OTHER INCOME | |
| | |
| |
Interest income | |
| | |
| |
| | | | | | |
Other income, net | |
| | | | |
| | | | | | |
NET LOSS | | $ | ( | | $ | ( |
| | | | | | |
Net loss per common share- basic and diluted | | $ | ( | | $ | ( |
| | | | | | |
Weighted average common shares outstanding- basic and diluted | |
| | | | |
See accompanying notes to the condensed financial statements
4
NanoViricides, Inc.
Condensed Statement of Changes in Stockholders’ Equity
For the three months ended September 30, 2026
(Unaudited)
| | | | | | | | | | | | | | | | | | | |
| | Series A Preferred | | Common Stock: | | | | | | | | | | ||||||
| | Stock: Par $0.00001 | | Par $0.00001 | | | | | | | |||||||||
| | Number | | | | Number | | | | Additional | | | | Total | |||||
| | of | | | | of | | | | Paid-in | | Accumulated | | Stockholders’ | |||||
| | Shares | | Amount | | Shares | | Amount | | Capital | | Deficit | | Equity | |||||
Balance, June 30, 2026 |
| | | $ | | | | | $ | | | $ | | | $ | ( | | $ | |
| | | | | | | | | | | | | | | | | | | |
Proceeds from sale of common stock in connection with equity financings net of issuance costs of $ | | — | | | — | | | | | | | | | | | — | | | |
| | | | | | | | | | | | | | | | | | | |
Series A preferred stock issued for employee stock compensation |
| | | | — | | — | | | — | | | | | | — | | | |
| | | | | | | | | | | | | | | | | | | |
Common stock issued for consulting and legal services rendered | | — | | | — | | | | | — | | | | | | — | | | |
| | | | | | | | | | | | | | | | | | | |
Warrants issued to Scientific Advisory Board |
| — | |
| — |
| — | |
| — | |
| | |
| — | |
| |
| | | | | | | | | | | | | | | | | | | |
Common shares issued for Directors fees |
| — | |
| — |
| | |
| — | |
| | |
| — | |
| |
| | | | | | | | | | | | | | | | | | | |
Net loss |
| — | |
| — |
| — | |
| — | |
| — | |
| ( | |
| ( |
| | | | | | | | | | | | | | | | | | | |
Balance, September 30, 2026 |
| | | $ | |
| | | $ | | | $ | | | $ | ( | | $ | |
See accompanying notes to the condensed financial statements
5
NanoViricides, Inc.
Condensed Statement of Changes in Stockholders’ Equity
For the three months ended September 30, 2025
(Unaudited)
| | | | | | | | | | | | | | | | | | | |
| | Series A Preferred | | Common Stock: | | | | | | | | | | ||||||
| | Stock: Par $0.00001 | | Par $0.00001 | | | | | | | |||||||||
| | Number | | | | Number | | | | Additional | | | | Total | |||||
| | of | | | | of | | | | Paid-in | | Accumulated | | Stockholders’ | |||||
| | Shares | | Amount | | Shares | | Amount | | Capital | | Deficit | | Equity | |||||
Balance, June 30, 2025 |
| | | $ | | | | | $ | | | $ | | | $ | ( | | $ | |
| | | | | | | | | | | | | | | | | | | |
Proceeds from sale of common stock in connection with equity financings net of issuance costs of $ | | — | | | — | | | | | | | | | | | — | | | |
| | | | | | | | | | | | | | | | | | | |
Series A preferred stock issued for employee stock compensation |
| | | | — | | — | | | — | | | | | | — | | | |
| | | | | | | | | | | | | | | | | | | |
Common stock issued for consulting and legal services rendered | | — | | | — | | | | | | | | | | | — | | | |
| | | | | | | | | | | | | | | | | | | |
Warrants issued to Scientific Advisory Board |
| — | |
| — |
| — | |
| — | |
| | |
| — | |
| |
| | | | | | | | | | | | | | | | | | | |
Common shares issued for Directors fees |
| — | |
| — |
| | |
| — | |
| | |
| — | |
| |
| | | | | | | | | | | | | | | | | | | |
Net loss |
| — | |
| — |
| — | |
| — | |
| — | |
| ( | |
| ( |
| | | | | | | | | | | | | | | | | | | |
Balance, September 30, 2025 |
| | | $ | |
| | | $ | | | $ | | | $ | ( | | $ | |
See accompanying notes to the condensed financial statements
6
NanoViricides, Inc.
Condensed Statements of Cash Flows
(Unaudited)
| | | | | | |
| | For the Three Months Ended | ||||
| | September 30, | ||||
| | 2026 | | 2025 | ||
CASH FLOWS FROM OPERATING ACTIVITIES: | | | | | | |
Net loss | | $ | ( | | $ | ( |
| | | | | | |
Adjustments to reconcile net loss to net cash used in operating activities | |
| | | | |
Preferred shares issued as compensation | |
| | | | |
Common shares issued as compensation and for services | |
| | | | |
Warrants granted to Scientific Advisory Board | | | | | | |
Depreciation | |
| | | | |
Amortization | | | | | | |
Changes in operating assets and liabilities: | |
| | |
| |
Prepaid expenses | |
| ( | | | ( |
Other assets | |
| | | | |
Accounts payable | |
| | | | ( |
Accounts payable - related parties | |
| ( | | | |
Accrued expenses | |
| | | | |
Accrued expense – related parties | |
| | |
| — |
| | | | | | |
NET CASH USED IN OPERATING ACTIVITIES | |
| ( | | | ( |
| | | | | | |
CASH FLOWS FROM INVESTING ACTIVITIES: | | | | | | |
Purchase of property and equipment | | | — | | | ( |
NET CASH USED IN INVESTING ACTIVITIES | | | — | | | ( |
| | | | | | |
CASH FLOWS FROM FINANCING ACTIVITIES: | |
| | |
| |
Net proceeds from sale of common stock | | | | | | |
NET CASH PROVIDED BY FINANCING ACTIVITIES | | | | | | |
| | | | | | |
NET CHANGE IN CASH AND CASH EQUIVALENTS | |
| ( | | | ( |
Cash and cash equivalents at beginning of period | |
| | |
| |
Cash and cash equivalents at end of period | | $ | | | $ | |
NON CASH FINANCING AND INVESTING ACTIVITIES: | | | | | | |
Issuance of common stock for services rendered | | $ | — | | $ | |
See accompanying notes to the condensed financial statements
7
NANOVIRICIDES, INC.
September 30, 2026
NOTES TO THE CONDENSED FINANCIAL STATEMENTS
(Unaudited)
Note 1 – Organization and Nature of Business
NanoViricides, Inc. (the “Company”) is a clinical stage nano-biopharmaceutical company specializing in the discovery, development, and commercialization of drugs to combat viral infections using its unique and novel nanomedicines technology platform. The Company’s platform is based on host-mimicry, and thereby has uniquely enabled development of broad-spectrum antiviral drugs that the viruses would be unable to escape, a critical unmet need in antiviral therapeutics. NanoViricides possesses its own facility that supports research and development and drug discovery, drug candidate optimization, cGMP-compliant drug substance manufacturing, cGMP-compliant manufacturing and packaging of drug products for human clinical trials, and early commercialization. The Company has several drugs in various stages of development.
NanoViricides, Inc. is domiciled under the laws of the State of Delaware, with its principal operations located in the State of Connecticut. The Company’s fiscal year begins on July 1st and ends on the next June 30th of the calendar year. The Company operates in
Note 2 – Liquidity and Going Concern
The Company’s condensed financial statements have been prepared assuming that it will continue as a going concern, which contemplates continuity of operations, realization of assets and liquidation of liabilities in the normal course of business. As reflected in the condensed financial statements, the Company has an accumulated deficit at September 30, 2026 of approximately $
As of September 30, 2026, the end of the reporting period, the Company had approximately $
The ability of the Company to continue as a going concern is dependent upon controlling its overall expenses and identifying and securing additional financing.
The Company believes that it has several milestones including the anticipated successful completion of Phase II clinical trial of NV-387 as treatment for Mpox, and attendant top-line readout, and its recent commencement of Phase II Clinical Trials for treatment of Bundibugyo Ebola Virus. On or about August 4, 2026, the Company received regulatory approval to conduct this clinical trial from Autorité Congolaise de Réglementation Pharmaceutique (“ACOREP”), the pharmaceutical drug regulatory agency of the Democratic Republic of the Congo (“DRC”). The regulatory approval satisfied the conditions perfecting the Company’s financial commitment for the clinical trial. The Company has initiated the Phase IIA part of the trial. The trial is enrolling and is expected to continue to enroll persons exhibiting different disease severity levels.
8
The Company submitted an application for, “Orphan Drug Designations” (“ODD”) from the US FDA for three specific uses of NV-387, namely (1) NV-387 for Treatment of Mpox, (2) NV-387 for Treatment of Smallpox, and (3) NV-387 for Treatment of Measles. An ODD carries with it several benefits that include rapid FDA meetings, R&D tax breaks, and a Seven year exclusivity for the drug upon licensure. On April 27, 2026 the FDA granted the ODD to NV-387 for the treatment of Measles. In May 2026 the FDA granted the Rare Pediatric Disease Drug (RPDD) designation for NV-387 as a Treatment for Measles. We continuing to seek “Orphan Drug Designation” for the remaining two ODD applications for Mpox and Smallpox from the US FDA.
The Company plans to take advantage of the increased FDA interactions for filing appropriate Pre-IND applications and IND applications with the US FDA. We believe that the Mpox Phase II if successful, will likely enable a Phase II/III licensure clinical trial under the US FDA auspices upon completion, which may provide the shortest possible timeline for NV-387 licensure.
Further, the regulatory timelines for these three orphan diseases are likely to be substantially shorter than, say RSV, COVID, or Influenza drug development. This is because in the case of rare and orphan diseases, there are inherent limitations on the clinical trial recruitment due to the small number of available subjects, and the clinical protocols are designed to take this into account. Smaller number of subjects usually makes a clinical trial go faster, except in cases where the incidence rate of the disease cannot support the required recruitment level.
The Company has planned a novel Phase II clinical trial for evaluating NV-387 as a first line, empiric therapy for any respiratory viral infection, in an adaptive, basket-style clinical trial design. We are in discussions to execute this clinical trial in India. In a single and relatively low cost clinical trial, we will be able generate substantial, statistically declarative information, regarding NV-387 as a treatment for (1) Influenza, (2) COVID, (3) RSV, (4) human MetaPneumovirus (hMPV), along with valuable information on effectiveness of NV-387 against many other respiratory infections including Adenoviruses, Enteroviruses, and others, depending upon the rates of incidence in the incoming patients. NV-387 can then progress towards licensure individually against RSV, Influenza, COVID, and other respiratory viruses under the US FDA and internationally.
The Company executes its plans in a manner consistent with available resources, which can lead to reshuffling of priorities in its programs. Nevertheless, the Company has in the past and will continue to progress towards its goal of revolutionizing antiviral therapeutics.
Management believes that as these various milestones are achieved, the Company would likely experience improvement in the liquidity of the Company’s stock, and such improvement, if any, would enhance the Company’s ability to raise funds on the public markets at terms that may be favorable to the terms offered at present.
Management is actively exploring additional required funding through non-dilutive grants and contracts, partnering, as well as debt or equity financing pursuant to its plan. There is no assurance that we will be successful in obtaining sufficient financing on terms acceptable to us to fund continuing operations.
Management believes that it has on-going access to the capital markets including the “At-The-Market” (ATM) agreement with D. Boral Capital LLC, the Sales Agent.
There can be no assurance that the Company’s plans will not change or that changed circumstances will not result in the depletion of its capital resources more rapidly than it currently anticipates. The Company will need to raise additional capital to fund its long-term operations and research and development plans including human clinical trials for its various drug candidates until it generates revenue that reaches a level sufficient to provide self-sustaining cash flows. There can be no assurance that the Company will be able to raise the necessary capital or that it will be on acceptable terms. The accompanying financial statements do not include any adjustments that may result from the outcome of such unidentified uncertainties.
9
Note 3 - Summary of Significant Accounting Policies
Basis of Presentation – Interim Financial Information
The accompanying unaudited interim condensed financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission for Interim Reporting. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim condensed financial statements furnished reflect all adjustments (consisting of normal recurring accruals) that are, in the opinion of management, considered necessary for a fair presentation of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. The accompanying condensed financial statements and the information included under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations” should be read in conjunction with the Company’s audited financial statements and related notes included in the Company’s Form 10-K for the fiscal year ended June 30, 2026 filed with the SEC on September 28, 2026.
The June 30, 2026 year-end balance sheet data in the accompanying interim condensed financial statements was derived from the audited financial statements.
For a summary of significant accounting policies, see the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2026 filed on September 28, 2026.
Net Loss per Common Share
Basic net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock and potentially outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through warrants and convertible preferred stock.
The following table shows the number of potentially outstanding dilutive common shares excluded from the diluted net loss per common share calculation, as they were anti-dilutive:
| | | | |
| | Potentially Outstanding Dilutive Common Shares | ||
| | For the | | For the |
| | Three Months | | Three Months |
| | Ended | | Ended |
| | September 30, 2026 | | September 30, 2025 |
Warrants |
| | | |
Warrants (Participating Securities) | | | — | |
Total Warrants | | | | |
The Company has
Segment and geographic information
Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the CODM, or decision making group, in deciding how to allocate resources in assessing performance. The Company has
10
Segment revenue, profit or loss, significant segment expenses and other segment items - The accounting policies of the Company’s single operating and reportable segment are the same as those described in this Summary of Significant Accounting Policies. The Company’s method for measuring segment profitability includes net income (loss), which the CODM uses to assess performance and make decisions for resource allocation, consistent with the measurement principles for net income (loss) as reported on the Company’s statement of operations. The significant expenses regularly reviewed by the CODM are consistent with those reported on the Company’s statement of operations, and expenses are not regularly reviewed on a more disaggregated basis for purposes of assessing segment performance and deciding how to allocate resources. The measure of segment assets reviewed by the CODM is total assets, as reported on the Company’s balance sheet.
Recently Issued Accounting Pronouncements
The Company considers the applicability and impact of all Accounting Standard Updates (“ASU’s”). ASU’s not discussed below were assessed and determined to be either not applicable or are expected to have minimal impact on the Company’s financial statements.
ASU 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, which requires public business entities (PBEs) to disclose, in interim and annual reporting periods, additional information about certain expenses in the notes to financial statements. The requirements of ASU 2024-03 apply to all public business entities. The ASU requires disaggregated disclosure of income statement expenses for public business entities (PBEs). The ASU does not change the expense captions an entity presents on the face of the income statement; rather, it requires disaggregation of certain expense captions into specified categories in disclosures within the footnotes to the financial statements. ASU 2024-03 is effective for all PBEs for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. While the Company is currently evaluating the adoption impact of this ASU on its financial statements, the preliminary assessment is that the adoption of this standard is not expected to have a material effect on the Company’s financial statements and the Company’s disclosures.
Recently Adopted Accounting Standards
Improvements to Income Tax Disclosures
In December 2023, the FASB issued ASU 2023-09, “Improvements to Tax Disclosures” (Topic 740). The new guidance is intended to enhance the transparency and decision usefulness of income tax disclosures through changes to the rate reconciliation and the income taxes paid information disclosed. The Company adopted this ASU as of July 1, 2025 and the impact on the financial statements is not material, beyond certain expanded disclosure.
Note 4 - Related Party Transactions
Related Parties
Related parties with whom the Company had transactions are:
| | |
Related Parties | | Relationship |
Dr. Anil Diwan | | President and Executive Chairman, significant stockholder through his ownership of TheraCour, and Director |
| | |
TheraCour Pharma, Inc. (“TheraCour”) | | An entity owned and controlled by Dr. Anil Diwan |
| | |
Karveer Meditech Private Limited (“KMPL”) | | An entity where Dr. Anil Diwan is a passive investor and advisor without operating control |
| | |
Meeta Vyas | | Chief Financial Officer, does not claim beneficial ownership of stock through her husband, Dr. Anil Diwan |
11
| | | | | | |
| | For the three months ended | ||||
| | September 30, | | September 30, | ||
| | 2026 | | 2025 | ||
Property and Equipment |
| | | | | |
| | | | | | |
During the reporting period, TheraCour acquired property and equipment on behalf of the Company from third party vendors and transferred such property and equipment, at cost to the Company | | $ | — | | $ | |
| | | | | | |
| | As of | ||||
| | September 30, | | June 30, | ||
| | 2026 | | 2026 | ||
Accounts Payable – Related Party-TheraCour | | | | | | |
| | | | | | |
Pursuant to an Exclusive License Agreement entered into with TheraCour, the Company was granted exclusive licenses for technologies developed by TheraCour for the virus types: HIV, HCV, Herpes, Asian (bird) flu, Influenza and rabies. On November 1, 2019, the Company entered into the VZV Licensing Agreement with TheraCour. In consideration for obtaining these exclusive licenses it was agreed: (1) that TheraCour can charge its costs (direct and indirect) plus no more than | | $ | | | $ | |
| | | | | | |
| | For the three months ended | ||||
| | September 30, | | September 30, | ||
| | 2026 | | 2025 | ||
Research and Development Costs - Related Party | | | | | | |
| | | | | | |
Development fees and other costs charged by TheraCour pursuant to the license agreements between TheraCour and the Company for the development of the Company’s drug pipeline. | | $ | | | $ | |
License Milestone Fee – Related Party
On February 12, 2024, the Company entered into an Amendment to the COVID License Agreement with TheraCour dated September 7, 2021, whereby any further cash milestone payments that would be earned upon milestone event would only become payable upon the Company having sufficient revenues, with only a portion of revenues to be used for satisfying such milestone payments.
12
Clinical Trial Costs - Related Party
| | | | | | |
| | For the three months Ended | ||||
| | September 30, | | September 30, | ||
| | 2026 | | 2025 | ||
Clinical trial related and other costs were charged by KMPL pursuant to the license agreement between the Company and KMPL for the clinical trial related costs that have been incurred for Phase 1a/1b clinical trials in India as of June 30, 2026. On May 26, 2026 KMPL invoiced and the Company paid an advance payment under the Covid Phase 1 Budget provisions of $ | | $ | — | | $ | — |
| | | | | | |
| | As of | ||||
| | September 30, | | June 30, | ||
| | 2026 | | 2026 | ||
Clinical Trial Costs Accrued - Related Party |
| | |
| | |
| | | | | | |
Clinical trial costs accrued-related party includes expenses for clinical trial expenses of $ | | $ | | | $ | — |
Line of Credit - Related Party
On November 13, 2023, the Company’s President and CEO, Dr. Anil R. Diwan, entered into a Line of Credit Agreement whereby Dr. Diwan agreed to provide a standby Line of Credit to the Company in the maximum amount of $
On September 23, 2024 and becoming effective as of September 20, 2024, the Company, pursuant to Article 2.5 of the Company’s Line of Credit Agreement with Dr. Anil R. Diwan, signed an Amendment Agreement which increased the available line of credit from $
There were
13
Note 5 - Property and Equipment
Property and equipment, stated at cost, less accumulated depreciation consisted of the following:
| | | | | | |
| | September 30, | | June 30, | ||
| | 2026 | | 2026 | ||
GMP Facility | | $ | | | $ | |
| | | | | | |
Land | |
| | | | |
| | | | | | |
Office Equipment | |
| | | | |
| | | | | | |
Furniture and Fixtures | |
| | | | |
| | | | | | |
Lab Equipment | |
| | | | |
| | | | | | |
Total Property and Equipment | |
| | | | |
| | | | | | |
Less Accumulated Depreciation | |
| ( | | | ( |
Property and Equipment, Net | | $ | | | $ | |
Depreciation expense for the three months ended September 30, 2026 and 2025 was $
Note 6 – Intangible Assets
Intangible assets, net consists of the following:
| | | | | | | | | | | | | | | | | | |
| | September 30, 2026 | | | | | June 30, 2026 | | | | ||||||||
| | Finite Lived | | Indefinite Lived | | | | Finite Lived | | Indefinite Lived | | | ||||||
| | Intangible Assets | | Intangible Assets | | Total | | Intangible Assets | | Intangible Assets | | Total | ||||||
Intangible Assets | | $ | | | $ | | | $ | | | $ | | | $ | | | $ | |
Less Accumulated Amortization | | | ( | | | — | | | ( | | | ( | | | — | | | ( |
Intangible Assets, Net | | $ | | | $ | | | $ | | | $ | | | $ | | | $ | |
Amortization expense amounted to $
NanoViricides, Inc.’s intangible assets include acquired licenses and capitalized patent costs representing legal fees associated with filing patent applications. Intangible assets with finite lives, licenses and patent costs, are amortized using the straight-line method over the estimated economic lives of the assets, which range from seventeen to
Intangible assets determined to have indefinite useful lives, primarily patent costs, are not amortized but are tested for impairment annually, or more frequently if events or changes in circumstances indicate the asset may be impaired. The Company accounts for patent costs in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) ASC 350-30, General Intangibles Other than Goodwill. The Company will begin amortizing the patent costs when they are brought to the market or otherwise commercialized.
The Company does assess the recoverability of intangible assets with indefinite lives annually in the fourth quarter of each fiscal year, or more often if indicators warrant, by determining whether the fair value of each of the intangible assets, as a unit, supports its carrying value. In accordance with ASC 350, each year the Company may assess qualitative factors to determine whether it is more likely than not that the fair value of each patent is less than its carrying amount as a basis for determining whether it is necessary to complete quantitative impairment assessments.
14
Note 7 – Accrued expenses
Accrued expenses consisted of the following:
| | | | | | |
| | September 30, | | June 30, | ||
| | 2026 | | 2026 | ||
Personnel and compensation costs | | $ | | | $ | |
Consultant | | | | | | |
Clinical trial costs | | | | | | — |
Other | | | — | | | |
| | $ | | | $ | |
Note 8 - Equity Transactions
On July 1, 2026 the Company and Dr. Anil Diwan entered into an extension of his employment agreement for a period of
At The Market Sales Agreement
On July 17, 2026, the Company entered into an At The Market Issuance Sales Agreement (the “Sales Agreement”) with D. Boral Capital LLC (the “Sales Agent”), pursuant to which the Company may offer and sell, from time to time, through or to the Sales Agent, shares of the Company’s common stock, par value $
On July 17, 2026, the Company filed a prospectus supplement with the U.S. Securities and Exchange Commission (the “Commission”) in connection with the Sales Agreement (the “Prospectus Supplement”) under its existing shelf Registration Statement on Form S-3 (File No. 333-296550) (the “Registration Statement”) initially filed with the Commission on June 5, 2026 and declared effective on June 15, 2026, and the base prospectus included therein.
Sales of Common Stock, if any, may be made by any method permitted by law deemed to be an “at the market” offering, including sales made directly on the NYSE American or on any other existing trading market for the Common Stock. The Sales Agent may also sell shares of Common Stock by any other method permitted by law, including in privately negotiated transactions, with the Company’s prior written consent.
The Company will instruct the Sales Agent as to the parameters of each sale of shares of Common Stock under the Sales Agreement by delivery of a placement notice. The Sales Agent will use its best efforts consistent with its normal trading and sales practices and applicable law to sell shares of Common Stock under the Sales Agreement on the terms and subject to the conditions set forth therein. The Company has agreed to pay the Sales Agent a commission equal to
15
Registered Direct Offering
On July 24, 2026, the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) pursuant to which the Company agreed to sell and issue to the Investor in a registered direct offering: (i)
Pursuant to the July Securities Purchase Agreement, the Company has agreed for a period of
In addition, the Company agreed that within thirty (
The Company allocated the aggregate proceeds between the common stock and warrants based on their respective relative fair values on the issuance date. The fair value of the warrants was estimated using the Black-Scholes option pricing model. Of the aggregate proceeds, approximately $
The Offering closed on July 27, 2026 (the “Closing Date”). The Pre-Funded Warrants were exercised at closing. The company issued
For the three months ended September 30, 2026, the Company’s Board of Directors authorized the issuance of
There is currently no market for the shares of Series A preferred stock and they can only be converted into shares of common stock upon a change of control of the Company as more fully described in the Certificate of Designation. The Company, therefore, estimated the fair value of the Series A preferred stock granted to various employees and others on the date of grant. The conversion of the shares is triggered by a change of control. The fair value of the Series A Convertible preferred stock at each issuance was estimated based upon the price of the Company’s common stock after an application for a reasonable discount for lack of marketability.
The Scientific Advisory Board was granted in August 2026 fully vested warrants to purchase
16
The Company estimated the fair value of the warrants granted to the Scientific Advisory Board on the date of grant using the Black-Scholes Option-Pricing Model with the following assumptions:
| | | |
Expected life (years) | |
| |
| | | |
Expected volatility | | | % |
| | | |
Expected annual rate of quarterly dividends | | | % |
| | | |
Risk-free rate(s) | | | % |
For the three months ended September 30, 2026, the Company’s Board of Directors authorized the issuance of
For the three months ended September 30, 2026, the Company’s Board of Directors authorized the issuance of
Note 9 - Common Stock Warrants
| | | | | | | | | | |
| | | | Weighted | | | | | | |
| | | | Average | | Weighted | | | | |
| | | | Exercise | | Average | | | | |
| | | | Price | | Remaining | | Aggregate | ||
| | Number of | | per share | | Contractual Term | | Intrinsic Value | ||
Common Stock Warrants | | Shares | | ($) | | (years) | | ($) | ||
Outstanding and exercisable at June 30, 2026 | | | | $ | | | | $ | | |
| | | | | | | | | | |
Granted | | | | | | | | | | |
| | | | | | | | | | |
Issued to investors | | | | | | | | | | |
| | | | | | | | | | |
Expired | | ( | | | | | — | | | |
Outstanding at September 30, 2026 ( | | | | $ | | | | $ | | |
Of the outstanding warrants at September 30, 2026,
Note 10 - Commitments and Contingencies
Legal Proceedings
From time to time, we are subject to various legal proceedings arising in the ordinary course of business, including proceedings for which we have insurance coverage. There are no pending legal proceedings against the Company to the best of the Company’s knowledge as of the date hereof and to the Company’s knowledge no action, suit or proceeding has been threatened against the Company that we believe will have a material adverse effect to our business, financial position, results of operations, or liquidity.
17
Employment Agreements
As of July 1, 2026, NanoViricides, Inc. entered into an Extension Agreement (the “Extension”) of the 2025 Employment Agreement with Dr. Anil Diwan entered into on July 1, 2018 (the “Employment Agreement”) to continue to serve as the President and Executive Chairman of the Company, effective July 1, 2026 under the same general terms and conditions. The Extension provides that Dr. Diwan will continue to serve as the Company’s President until June 30, 2027 at an annual base salary of $
On March 3, 2010, the Company entered into an employment agreement with Dr. Jayant Tatake to serve as Vice President of Research and Development. The employment agreement provides for a term of
As of July 1, 2026, NanoViricides, Inc. consummated an Extension to the CFO Agreement with its Chief Financial Officer Meeta Vyas effective July 1, 2026 (the “CFO Agreement Extension”) of the agreement originally entered into on May 30, 2013. The agreement is renewable on an annual basis. The original agreement provided for a term of
License Agreements
The Company is dependent upon its license agreements with TheraCour (See Notes 4). If the Company lost the right to utilize any of the proprietary information that is the subject of the TheraCour license agreement on which it depends, the Company will incur substantial delays and costs in development of its drug candidates. On November 1, 2019, the Company entered into a VZV License Agreement with TheraCour for an exclusive license for the Company to use, promote, offer for sale, import, export, sell and distribute products for the treatment of VZV derived indications. Process development and related work will be performed by TheraCour under the same compensation terms as prior agreements between the parties, with no duplication of costs allowed.
On September 7, 2021, the Company entered into a COVID-19 License Agreement to use, promote, offer for sale, import, export, sell and distribute drugs that treat COVID-19 infections, using TheraCour’s proprietary as well as patented technology and intellectual property. The discovery of ligands and polymer materials as well as formulations, the chemistry and chemical characterization, as well as process development and related work will be performed by TheraCour under the same compensation terms as prior agreements between the parties, with no duplication of costs allowed.
18
On March 27, 2023 the Company entered into a license agreement with KMPL wherein the Company granted to KMPL a limited, non-transferable, exclusive license for the use, sale, or offer of sale in India of the Company’s
On February 12, 2024, the Company entered into an Amendment to the COVID License Agreement with TheraCour dated September 7, 2021, whereby any further cash milestone payments that would be earned upon milestone event would only become payable upon the Company having sufficient revenues, with only a portion of revenues to be used for satisfying such milestone payments.
On September 23, 2024 and effective as of September 20, 2024, the Company entered into a “Memorandum of Understanding for All Antivirals Drug Development” (the MoU) with TheraCour that granted to the Company, a limited, non-assignable, non-sublicensable, exclusive Right of First Refusal to License to any antiviral drugs in development or to be developed by TheraCour for research and development purposes only, for all as-yet unlicensed viral infection treatment indications. The MoU also clarified the roles and responsibilities of the Parties and essentially codified the process that the parties have adopted since inception. The MoU further codified the treatment of all future milestone payments arising from any current or future license agreements to TheraCour to be consistent with the principles adopted in the February 12, 2024 Amendment to the COVID-19 License Agreement.
Clinical Trial Agreements
On June 20, 2024, we had entered into a Master Services Agreement (KMPL-MSA) with KMPL. This MSA enabled starting new projects in a specified manner without having to go through a complete agreement process.
In August, 2024, in the context of initiating a Phase II Clinical Trial for evaluating NV-387 as a Treatment for Mpox infections in the African Region, KMPL introduced the Company to Om Sai Clinical Research Private Limited, of Sangli, Maharashtra, India (“Om Sai”), a CRO with long-standing clinical trial site relationships in the African region where an MPox pandemic had broken out and was declared a Public Health Emergency of International Concern (“PHEIC”) by the WHO on August 16, 2024. The Mpox epidemic is still in progress DRC, although the case loads have decreased substantially.
In October 2024, we authorized KMPL to serve as Project Manager for our Phase II clinical trial of Mpox in DRC under the KMPL-MSA. KMPL brought in Om Sai Clinical Research Pvt. Ltd., India, to serve as CRO for this clinical trial. According to this agreement, we will pay KMPL project management fees of up to
On October 10, 2024 a Phase II Clinical Trial Contract for the MPox Clinical Trial evaluating NV-387, was entered into between Om Sai Clinical Research Private Limited, as the CRO, and the Company. Om Sai is an independent third party and is not a related party.
The Company has incurred approximately $
On May 16, 2026, a new outbreak of a novel strain of the Ebola Bundibugyo virus was found to have started leading the WHO to declare a PHEIC for Ebola. The Company determined that NV-387 had a significant likelihood of being able to make a difference in this Ebola epidemic, since it was demonstrated to be a broad-spectrum antiviral agent in several animal studies, and because NV-387 is only anti-Ebola drug candidate that can be administered orally.
19
On or about May 24, 2026, the Company engaged KMPL as the Clinical Trial Project Manager, and Om Sai as the CRO to lead the clinical trial, for Phase II Ebola Project. This, the Company’s second Phase II clinical trial. This Phase II Clinical Trial is for evaluating NV-387 Oral Gummies for the treatment of indications of the Bundibugyo Ebola virus and other Ebola viruses. The Company negotiated with KMPL that we will pay KMPL project management fees of up to
The Mpox and Ebola Phase II Clinical Trial Projects, as well as retaining KMPL as project managers for both trials, and retaining Om Sai as CRO for both trials have been approved by the Board of directors as we progressed in the various activities.
In June 2026, the Company was informed by the specially constituted Pillar Committee for Ebola Response in DRC that its proposal for the Phase II clinical trial of NV-387 Oral Gummies as a Treatment for Ebola was accepted for consideration and that the Company may proceed to obtain first, an Ethics Committee approval and then, the ACOREP local regulatory body approval for initiating the clinical trial. On or about July 4, 2026, the Company received Ethics Committee approval.
On or about July 7, 2026 the Company made an advance payment to initiate certain procedures that were required prior to filing the application for regulatory approval of the clinical trial. Subsequently, on July 10, 2026, the application was submitted to ACOREP, and on or about August 4, 2026, the Company received regulatory approval to conduct the clinical trial from ACOREP. The regulatory approval satisfied the conditions perfecting the Company’s financial commitment for the clinical trial.
The Company had incurred expenses of approximately $
Note 11 – Subsequent Event
At-the-Market Offering
As discussed in Note 8 to the financial statements, on July 17, 2026, the Company entered into an At-The –Market Issuance Sales Agreement (“the Sales Agreement”) with D. Boral Capital, LLC (the “Sales Agent”), pursuant to which the Company may offer and sell, from time to time, through or to the Sales Agent in an at-the-market offering (the “ATM Offering”).
On November 11, 2026, the Company commenced sales of common stock pursuant to the ATM Offering. The shares are being offered and sold pursuant to the Prospectus dated June 15, 2026, and the prospectus supplement dated July 17, 2026 and amended on July 27, 2026, and further amended October 21, 2026, under the Company’s shelf registration statement on Form S-3, as amended (File No. 333-296550).
From November 11, 2026 through November 13, 2026 the Company sold
20
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following discussion should be read in conjunction with the information contained in the condensed financial statements of the Company and the notes thereto appearing elsewhere herein and in conjunction with the Management’s Discussion and Analysis of Financial Condition and Results of Operations set forth in the Company’s Annual Report on Form 10-K for the year ended June 30, 2026. Readers should carefully review the risk factors disclosed in the Company’s Form 10-K and other documents filed by the Company with the SEC.
As used in this report “Safety”, “Efficacy”, “Effectiveness” and related terms refer to the results of the Company’s research studies and these statements have not been evaluated by regulatory bodies including the FDA that have the authority for the purpose of commercial use of the drugs.
As used in this report, the terms “Company”, “we”, “our”, “us” and “NNVC” refer to NanoViricides, Inc., a Delaware corporation.
PRELIMINARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Report contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical fact made in this report are forward looking. In particular, the statements herein regarding industry prospects and future results of operations or financial position are forward-looking statements. These include statements about our expectations, beliefs, intentions or strategies for the future, which we indicate by words or phrases such as “anticipate,” “expect,” “intend,” “plan,” “will,” “we believe,” “Company believes,” “management believes” and similar language. These forward-looking statements can be identified by the use of words such as “believes,” “estimates,” “could,” “possibly,” “probably,” “anticipates,” “projects,” “expects,” “may,” “will,” or “should,” or other variations or similar words. No assurances can be given that the future results anticipated by the forward-looking statements will be achieved. Forward-looking statements reflect management’s current expectations and are inherently uncertain. The forward-looking statements are based on the current expectations of NanoViricides, Inc. and are inherently subject to certain risks, uncertainties and assumptions, including those set forth in the discussion under “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in this report. Actual results may differ materially from results anticipated in these forward-looking statements. We base the forward-looking statements on information currently available to us, and we assume no obligation to update them.
Investors are also advised to refer to the information in our previous filings with the Securities and Exchange Commission (SEC), especially on Forms 10-K, 10-Q and 8-K, in which we discuss in more detail various important factors that could cause actual results to differ from expected or historic results. It is not possible to foresee or identify all such factors. As such, investors should not consider any list of such factors to be an exhaustive statement of all risks and uncertainties or potentially inaccurate assumptions.
Organization and Nature of Business
NanoViricides, Inc. (the “Company”, “NanoViricides”, “we,” or “us”) was incorporated in Nevada on April 1, 2005, and redomiciled to Delaware effective May 30, 2023.
NanoViricides, Inc. (the “Company”) is a clinical stage nano-biopharmaceutical company specializing in the discovery, development, and commercialization of drugs to combat viral infections using its unique and novel nanomedicines technology platform. The Company’s platform is based on host-mimicry, and thereby has uniquely enabled development of broad-spectrum antiviral drugs that the viruses would be unable to escape, a critical unmet need in antiviral therapeutics. NanoViricides possesses its own facility that supports research and development and drug discovery, drug candidate optimization, cGMP-compliant drug substance manufacturing, cGMP-compliant manufacturing and packaging of drug products for human clinical trials, and early commercialization. The Company has several drugs in various stages of development.
NanoViricides, Inc. is domiciled under the laws of the State of Delaware, with its principal operations located in the State of Connecticut. The Company’s fiscal year begins on July 1st and ends on the next June 30th of the calendar year. The Company operates in one reportable business segment. Our corporate offices are located at 1 Controls Drive, Shelton, Connecticut 06484 and our telephone number is (203) 937-6137. Our website is located at http://www.nanoviricides.com. We do not incorporate by reference into this Quarterly Report the information on or accessible through our website, and you should not consider it part of this Quarterly Report.
On September 25, 2013, the Company’s common stock began trading on the New York Stock Exchange American under the symbol, “NNVC”.
21
We are a clinical stage nano-biopharmaceutical company developing (a) host-mimetic, and (b) direct-acting, nanomachines capable of dismantling the virus without assistance from the human immune system.
Virus Escaping a Nanoviricide Drug is Unlikely
Viruses escaping vaccines, antibodies, and small chemical drugs has been a major problem in conquering viral infections. This is because viruses continuously change in the field, rendering these medical countermeasures ineffective. This was repeatedly observed during the COVID pandemic.
Nanoviricides technology solves this problem of virus escape by mimicking the essential, conserved, host-side features of the receptors that a particular virus uses. A virus is highly unlikely to escape the nanoviricide drug that we create against it by generating mutants and variants in the field, because all of its variants still require the same signature host features that our drugs mimic.
Nanoviricides Drugs Are Designed So that They Can be Used in Potentially All Segments of Patient Population
As a direct-acting antiviral, a nanoviricide drug is not expected to interfere with human bodily systems or enzymes, which is expected to result in significant levels of safety, unlike most of the antiviral drugs. Additionally, a nanoviricide is designed and constructed so that its components are biocompatible and metabolizable without toxicity.
Phase I human clinical trial of NV-387 to evaluate safety and tolerability in healthy subjects was completed with no adverse events, meeting or exceeding safety and tolerability objectives of the trial. In non-clinical IND-enabling studies NV-387 as well as NV-HHV-1 have been found to be extremely good in terms of their effects on animal physiology, clinical and blood chemistry, as well as no organ-specific negative findings. These clinical and non-clinical findings validate our nanoviricide platform as being capable of clinically relevant development of safe and well tolerated drugs.
Such good safety and tolerability profile of nanoviricide drugs is expected to enable use of nanoviricide drugs in all segments of patient populations, potentially from infants to children to adolescents to healthy adults to geriatric patients1.
Nanoviricides Drugs Can be Used in Patients with Co-morbidities or Patients with Immune Compromise Status
A nanoviricide drug is designed to complete the task of destroying the virus particle, without requiring assistance from a functioning immune system of the patient. Any viral infection that causes significant pathology does so by virtue of host immune system disrepair, either pre-existing, or caused by the virus itself. Therefore, nanoviricides can be expected to be superior to approaches such as vaccines and antibodies that require a good functional host immune system for antiviral response. Vaccines require healthy immune system so that appropriate antibody-generating memory cells can be created, stored, and deployed in case of infection later. Antibodies used as drugs decorate the virus particle and require a healthy immune system to handle the virus-antibody complexes thus formed.
Since nanoviricide drugs are designed as chemical nanomachines that function without reliance on the patient’s physiology, these drugs are expected to be useful even for patients with co-morbidities such as diabetes, heart disease, and others, as well as for immune-compromised patients including those with HIV/AIDS or “immune amnesia” such as resulting from measles or other prior infections.
These distinctive features that set nanoviricides apart from the entire world of current antiviral approaches are made possible by our novel nanoviricide chemical nanomachine technology platform.
In contrast, almost all antivirals available today or in development with conventional methodologies have shortcomings of virus escape, limited eligible patient population, as well as limited responding patient population.
1 Specific non-clinical studies are required by regulatory agencies for allowing testing of a novel drug in (i) pediatric patients, (ii) newborns and infants, and (iii) women of reproductive age. We intend to perform these studies at appropriate regulatory stages of development of the nanoviricides drugs as is customary.
22
After decades of development, this novel nanoviricide technology is now advancing through clinical stages towards regulatory approvals.
Broad and Expanding Drug Pipeline for Sustained Commercial Success and Cures of Viral Infections
The host-mimicry nanoviricide platform has enabled development of (i) an extremely broad-spectrum antiviral drug, NV-387, which is now in multiple Phase II clinical trials, as well as virus-family-specific drugs that include (ii) a drug designed to work against most if not all viruses in the Herpesviriadae family, namely, NV-HHV-1, and (iii) a drug designed to work against almost all if not all variants of HIV, namely, NV-HIV-1. NV-HIV-1 (HIV-1, 2; all mutants).
Nanoviricide drug development against other viruses or virus families would be rapid because of the modular drug development methodology of the nanoviricide platform in which the virus specific ligand is chemically attached to a standardized “cassette” polymeric micelle forming molecule to create the new drug.
Large Market Sizes2
NV-387 alone, because of its broad spectrum activity against Influenza, RSV, COVID, Smallpox, Mpox (Monkeypox), Measles, Ebola/Marburg, and potentially many other viruses, is estimated to have market size of approximately $23 Billion by 2030 based on available market estimates. Additionally, NV-HHV-1 could target a potential market size exceeding $4 Billion by 2030, and NV-HIV-1 target market size is estimated at approximately $13 Billion by 2030, based on external market reports.
Lead Drug NV-387 is Broad-Spectrum by Design with Host Mimicry
The reason for the exceedingly broad-spectrum activity of NV-387 lies in the design of the drug. All of these distinctly different viruses utilize HSPG (heparan sulfate proteoglycans) for cell infection; so do H5N1, H7N9, the highly pathogenic influenza viruses, and even the Measles virus. In fact, it is well known that over 90-95% of human pathogenic viruses all utilize either HSPG or similar, related Sulfated Proteoglycans (“SPG”) as the initial attachment sites to be able to infect human cells. NV-387 mimics the key features of SPG that are required for the virus binding. No matter how much a virus mutates, it continues to use SPG for initial attachment.
NV-387 was designed to be active against many viruses that affect humans. This is because NV-387 mimics a host-side feature of sulfated proteoglycans (“S-PG”). S-PG are a class of biochemicals that are used by most of the viruses as “Attachment Receptor(s)” before the viruses can infect cells and cause disease. S-PG class includes Heparan Sulfate Proteoglycans (HSPG), Chondroitin Sulfate, Dermatan Sulfate, and others. Over 90% of human pathogenic viruses are known to use HSPG as the first attachment site to cause infection into human cells. Thus, NV-387 is designed to have an extremely broad range of viruses against which it could be potentially clinically active.
2 These market size estimates are derived based on the following reports or press releases, among others:
(a).Influenza A Infections – Market Insight, Epidemiology and Market Forecast to 2032, DelveInsight, 2022, https://www.delveinsight.com/report-store/influenza-a-infections-market?utm_source=cision&utm_medium=pressrelease&utm_campaign=spr
(b).Respiratory Syncytial Virus (RSV) Therapeutics Market to 2031, GrowthPlusReports, 2023, https://www.growthplusreports.com/report/respiratory-syncytial-virus-rsv-therapeutics-market/8519.
(c).Herpes Simplex Virus Treatment Market Size...Forecast to 2030, GrandviewResearch, 2024, https://www.grandviewresearch.com/industry-analysis/herpes-simplex-virus-treatment-market-report.
(d) Infectious Disease Therapeutics Market Size… to 2030, GrandviewResearch, 2024,
https://www.grandviewresearch.com/industry-analysis/infectious-disease-therapeutics-market.
23
Lead Drug NV-387 Demonstrated Excellent Non-Clinical Safety Data - Summary
In the non-clinical studies leading to the Phase I clinical trial, NV-387 was found to be non-immunogenic, non-allergenic, non-mutagenic, as well as non-genotoxic. No adverse effects were reported in GLP Safety-Toxicology studies in multiple animal models including non-human primates (NHP, Cynomolgus monkeys).
The NOAEL (No-Observed-Adverse-Events-Level) for slow I.V. injection of NV-387 was 1,200 mg/Kg and the MTD (Maximum Tolerable Dose) was 1,500 mg/Kg in rats, which are very high numbers (high is good). In addition, the NOAEL for Oral administration of NV-387 in rats was 4,500 mg/Kg and the MTD for oral was 7,200 mg/Kg in rats.
Excellent Pediatric Non-Clinical Safety Data Demonstrated by Lead Drug NV-387 (Animal Study) - Summary
We reported in a press release on October 20, 2026, that in a recently completed Juvenile Mouse Pups Oral Repeat-Dose Safety/Tolerability study, the NOAEL was found to be at least as much as 1,230 mg/kg per dose administered three times daily, or 3,690 mg/kg/day, or a total cumulative drug exposure of 44,280 mg/kg over the 12 day dosing study period. This was actually the highest dose level tested. Therefore, a Maximum Tolerable Dose (MTD) could not be estimated.
These data wherein dosing was started in 4 or 5 days old mouse pups suggest that NV-387 could be dosed safely in children at least as young as 1 year old, based on animal study age alliteration metrics 3.
Thus, NV-387 is expected to be eligible for pediatric drug development, beginning with its use in pediatric populations in clinical trials to treat diseases including Mpox, Ebola, Measles, RSV, and others. We plan to apply for inclusion of small pediatric population cohorts in the forthcoming clinical trial applications.
NV-387 Regulatory Strategy
Revolutionary Broad-Spectrum Antiviral - Clinical Stage Lead Drug NV-387
Our clinical stage lead drug candidate, NV-387, is a broad-spectrum antiviral drug that has demonstrated strong activity in lethal lung viral infection animal model trials for the treatment of an extremely broad and wide variety of viruses.
This broad antiviral spectrum of NV-387 is reminiscent of the broad antibacterial spectrum of antibiotics such as penicillin and we believe NV-387 could revolutionize the treatment of viral infections the same way that penicillin revolutionized the treatment of bacterial infections.
The unique and revolutionary broad-spectrum antiviral effectiveness of NV-387 has been demonstrated in a number of lethal animal models that are relevant for human viral infections as varied as Influenza, Coronaviruses, RSV, Measles, as well as Monkeypox viruses (MPXV), and Smallpox virus (Variola). Its antiviral activity in these animal model studies was evident from NV-387-treated animals demonstrating significant increase in survival lifetime, as well as protection of lungs and reduction of clinical pathologies caused by the different viruses we have tested to date. Significant viral load reduction was also found to occur in instances where we were able to study these effects.
Multiple indications of NV-387 enable us to maximize return on investments. The Phase I safety and tolerability clinical trial would be generally applicable across all indications. All of IND-enabling non-clinical studies would also be reused, with the addition of animal model antiviral activity studies for the specific indication. The Chemistry, Manufacture, and Controls for the drug substance would remain substantially the same and potentially the drug product sections also could be reused. All of this enables significant savings in time, material, labor, and costs shared across the multiple programs, resulting in a significant improvement in return on investments (ROI) as compared to a drug developed for a single indication.
3 Barrows, PC and Schmitt, G, “Juvenile Nonclinical Safety Studies in Support of Pediatric Drug Development”, Chapter 2 in Jean-Charles Gautier (ed.), Drug Safety Evaluation: Methods and Protocols, Methods in Molecular Biology, vol. 1641, DOI 10.1007/978-1-4939-7172-5_2, © Springer Science+Business Media LLC 2017. This book chapter shows that mouse pups in 0-10 days of age are equivalent to human infants in the 0-28 days (newborns) for the purposes of pediatric equivalent animal model safety toxicology studies.
24
Such a wide spectrum of application of NV-387 as a treatment of viral infections has opened up a number of regulatory pathways for its development towards rapid drug licensure (i.e. regulatory approvals) with minimal capital outlays, with the potential for significant non-dilutive funding, and with the potential of rapid revenue generation (for details see below under “Possible Rapid Regulatory Paths, Non-Dilutive Funding, and Potential Revenues for NV-387”). In particular, development of NV-387 for the treatment of orphan diseases in the USA provides significant benefits upon approval, and can enable non-dilutive funding for the regulatory development work in some cases. We have therefore focused on the regulatory development of NV-387 towards diseases that are of importance in pandemic preparedness and response, and diseases with potential for bio-terrorism.
Development of a novel drug is a time taking and arduous process that goes through several regulatory steps. In summary, a Phase I clinical trial in healthy subjects is required in order to understand the safety and tolerability of the new drug in healthy subjects. This helps define the maximum dosing that may be allowed in the following Phase II clinical trial for the treatment of a particular disease. The Phase II clinical trial is designed to evaluate the safety and tolerability of the new drug, as well as the effectiveness of the new drug for a specified indication in a relatively small number of patients. If the drug is found to have a potential to be effective, and is found to be safe and well tolerated at the dosing regimen needed to achieve effectiveness, then a Phase III clinical trial is conducted in a larger number of patients, which is focused on ensuring that the drug is safe and well tolerated within the context of the disease, and to determine if it is truly effective in a varied population. If Phase III is successful, the drug sponsor would initiate a Marketing Authorization Application (MAA, also called a New Drug Application or NDA in the case of a new drug) to the appropriate regulatory agencies. The drug can only be sold in the authorized markets after the regulatory approval of the MAA/NDA.
In the case of drugs for “Orphan” diseases, the available patient population is small and therefore typically the clinical trials can be smaller than in the case of diseases that affect a wide proportion of population such as Influenzas. The US Government and US FDA have specific categories for Orphan Drug Designations and provide several benefits for such drugs. In addition, the US Government has provided special concessions and benefits for drugs targeted at pediatric diseases such as Measles. These benefits make the development of drugs for orphan diseases and for pediatric diseases appealing to us. We have therefore focused the regulatory development of NV-387 towards orphan diseases and pediatric diseases.
Taken together, our near term focus is on the development of NV-387 as a treatment for Monkeypox (Mpox), Smallpox, and Ebola/Marburg as diseases of importance in pandemic preparedness and response and for bio-terrorism; and Measles as an orphan and pediatric disease that has been causing multiple outbreaks in developed countries including the USA, and is endemic in large parts of the underdeveloped world.
In addition, as resources allow, we plan on developing NV-387 as a treatment for Viral Acute Respiratory Infections (Viral ARI) and their Severe forms (Viral SARI), irrespective of the underlying viral cause. This would enable NV-387 to become the first ever antiviral drug treatment that can be given at first visit without discerning the cause of viral infection, if successful, which would be as revolutionary as the introduction of broad-spectrum antibiotics for bacterial infections.
NV-387 Regulatory Developments – Summary and Current Status
NV-387 Phase I Clinical Trial Successfully Completed
NV-387 has successfully completed a Phase I clinical trial to evaluate its safety and tolerability in healthy subjects in India. There were no dropouts, and there were no reportable adverse events in this clinical trial of 72 subjects. These are some of the indications that the drug NV-387 was safe and well tolerated under conditions of the clinical trial. Two oral formulations, namely NV-387 Oral Gummies, and NV-387 Oral Syrup, were both tested in this clinical trial.
25
Thus, the drug NV-387, in both of the oral formulations studied, namely oral syrup and oral gummies (a soft solid form that dissolves in the mouth), is deemed to be safe and well tolerated and can be further advanced into Phase II clinical trials, as per communications with the Data Safety and Monitoring Board (DSMB) an independent expert review committee commissioned for this clinical trial. Our statement above regarding safety and tolerability will be evaluated, after we submit the final Phase I report, by the regulatory agency. The final clinical study report of the clinical trial is expected to be ready for submission soon. It was delayed because of the extreme workload of engaging into two separate Phase II clinical trials in response to emergency situations, namely, Mpox and Ebola, in DRC. The results of the Phase I clinical trial are consistent with our non-clinical findings.
NV-387 for the Treatment of Mpox, a Phase II Clinical Trial in Progress
NV-387 was also found to be highly effective against orthopoxvirus infection animal models which provide support for moving it forward towards licensure for its use in the treatment of (iv) Smallpox (caused by Variola virus), an important bioterrorism threat; as well as for evaluation as a treatment for Mpox (caused by the Monkeypox virus, MPXV), an important emerging threat.
Clade II Mpox is endemic in the Western world including the USA, but remains substantially limited to the MSM4 population and their sexual contacts. Clade I Mpox is a significantly more severe disease than the Clade II. Sporadic cases of Mpox Clade I have arisen in the USA in 2026, and community transmission is suspected, indicating a likely transition to sustained Clade Ib transmission in the United States, although a major outbreak has not happened, according to the CDC (https://www.cdc.gov/monkeypox/situation-summary/index.html.) A smallpox vaccine, Jynneos (aka Imvamune, Imvanex), is approved for Mpox by US FDA, and is recommended by CDC as a pre-exposure or post-exposure prophylaxis. Its pre-exposure vaccination effectiveness against Mpox Clade II was about 67% in MSM without HIV and about 45% in MSM with HIV (Lancet Infect Dis 2025; 25: 1106–15; https://doi.org/10.1016/S1473-3099(25)00180-X). Although it was fielded for Clade I Mpox in DRC in late 2025, its effectiveness against Clade I is not publicly known.
There is no approved drug for the treatment of Mpox Clade I or Clade II. Tecovirimat (TPOXX(r)), a drug approved for Smallpox using the US FDA “Animal Rule” for drugs that cannot be tested in human cases of a disease, has failed to demonstrate effectiveness against Mpox Clade I as well as Clade II in different clinical trials. A pan-African clinical trial called “MOSA” of another drug called brincidofovir 5, which is also approved by US FDA for Smallpox under the Animal Rule provision, that started in January, 2025, is currently ongoing. As of January 2026, according to a press release, this study’s Data and Safety Monitoring Board (DSMB) did not identify any new safety concerns after the first 50 patients were randomized, and the trial plans to enroll a further 50 patients in the first half of 2026, to perform interim efficacy analysis of brincidofovir 6. Brincidofovir requires constant physician care due to dose-limiting liver and gastro-intestinal toxicity concerns 7.
4 MSM means men having sex with men. MSM and their sexual contacts happens to be the target population in which both Mpox Clade I and Clade II occur. Mpox Clade II requires dermal friction or contact with open sores for transmission. Mpox Clade I is more easily transmissible upon contact with open sores and can transmit well outside of this target population into general population. In DRC, children are affected in large numbers during the continuing Mpox Clade I epidemic.
5 Fox T, Gould S, Princy N, Rowland T, Lutje V, Kuehn R. “Therapeutics for treating mpox in humans.” Cochrane Database of Systematic Reviews 2023, Issue 3. CD015769. DOI:10.1002/14651858.CD015769.
6 https://mpx-response.eu/a-first-safety-interim-analysis-of-mosa-shows-no-signal-of-safety-concerns-with-brincidofovir-a-potential-antiviral-to-fight-mpox/
7 According to the drug label (prescribing information), brincidofovir (“TEMBEXA”) carries a black box warning, and has warnings for elevations in hepatic transaminases and bilirubin (liver toxicity) and diarrhea and other gastrointestinal adverse events. Brincidofovir administration must be performed under physician care with continuous evaluation of liver toxicity. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214460s000,214461s000lbl.pdf
26
Thus there is an unmet medical need for a safe and effective drug against orthopoxviruses (Monkeypox Clade Ia/Ib and Clade IIa/IIb; as well as Smallpox). The US government currently stockpiles tecovirimat as well as brincidofovir in the Strategic National Stockpile (SNS) with annual repeat order contracts amounting to hundreds of millions of dollars. We believe that if NV-387 is found to be successful against Mpox Clade I in a clinical trial, then it could achieve US FDA approval for use in Smallpox, and would be eligible for potential US SNS acquisition contracts. The Monkeypox virus is considered a model virus for Smallpox regulatory development.
We initiated a clinical trial application process to allow us to conduct a Phase II clinical trial of NV-387 Oral Gummies as a Treatment of Mpox (Monkeypox) Disease (caused by hMPXV, the human Monkeypox virus), on or about April 2025, to obtain approval from the DRC regulatory agency, ACOREP, in response to the Monkeypox Clade I epidemic. This epidemic was declared a “Public Health Emergency of International Concern” (PHEIC) by the WHO in August, 2024, WHO ended the PHEIC declaration in September, 2025, based on a significant drop in Mpox cases across DRC. The Africa CDC however continued the Public Health Emergency of Continental Security (PHECS) citing new surges emerging in Ghana, Liberia, Kenya, Zambia, and Tanzania, with fresh introductions of the virus reported in Malawi, Ethiopia, Senegal, Togo, The Gambia, and Mozambique (https://africacdc.org/news-item/mpox-still-a-continental-emergency-africa-cdc-advisory-group-recommends/).
In November 2025, our NV-387 as a Treatment for Mpox Phase II clinical trial was approved by ACOREP. This clinical trial is registered in the Pan African Clinical Trials Registry database (pactr.samrc.ac.za). The unique identification number for this clinical trial is PACTR202609506749917.
We had to choose a remote clinical trial site to conduct the clinical trial because of lack of substantial number of Mpox cases in the Kinshasa area. This required us to conduct significant infrastructure development to bring the remote site to the status of an operational clinical trial center, including new laboratory equipment, IT infrastructure, as well as power and water infrastructure and appropriate accommodation enhancements for patient isolation.
During the reported quarter, the setup of a clinical pathology laboratory was completed at the Mpox NV-387 Phase II clinical trial site in DRC. Thereafter the Mpox Phase II clinical trial of NV-387 was officially initiated on or about September 23, 2026. The patient recruitment is arduous and slow because of several reasons. Firstly, in DRC, in the rural patients, Mpox lesions develop all over the body and are not readily distinguishable from Chickenpox or even from Measles because of the peculiarities of clinical presentation of these diseases in the local, low resource, nutritionally deficient, population. PCR testing is necessary to confirm an Mpox case. Secondly, in this remote area, the road transport and access conditions are primitive thus imposing delays in transporting the PCR samples to our lab for testing, and subsequently, if positive and if the patient agrees to participate upon the informed consent procedure, in bringing the patient to the clinical trial center for accommodation and treatment. Despite these difficulties, recruitment has begun very recently.
NV-387 for the Treatment of Ebola, another Phase II Clinical Trial in Progress
On May 17, 2026, the WHO declared a PHEIC for an Ebola outbreak in DRC that could have easily spread multi-nationally. The Ebola BDBV outbreak in DRC has resulted in 9,704 confirmed cases and 4,687 deaths, contributing to the global numbers of 9,735 confirmed cases and 4,690 confirmed deaths, as of October 20, 2026, according to the CDC 8. It is now the fastest growing and largest outbreak of Ebola in DRC, and is on track to become the largest Ebola outbreak globally eclipsing the 2014-2016 Ebola Zaire virus outbreak in West Africa that killed over 11,000 people, according to WHO. The Ebola BDBV spread has been restrained by severe travel restrictions imposed in DRC, and by nations around the world. Yet, an Ebola case escaped detection, traveled to Kenya and died in Nairobi, which has resulted in a small outbreak in Kenya, and there was a recent case in Nigeria. An early BDBV outbreak in Uganda was declared to have been over. This multi-national spread from East Africa to West Africa indicates the potential of global spread and the severity of the public health issue9. There are no cases of Ebola in the USA and the risk is very small if any.
8 https://www.cdc.gov/ebola/situation-summary/index.html.
9 https://www.npr.org/2026/10/20/g-s1-148975/nigeria-confirms-ebola-case.
27
This Ebola outbreak is caused by a novel variant of the Bundibugyo Ebolavirus (BDBV). As such, there are no approved drugs or vaccines for this Ebola virus disease. The vaccines and the two antibody treatments that were previously approved for Ebolavirus Zaire with clinical trials conducted during the 2014-2016 West African Ebola Zaire outbreak are not responsive to the current virus, and new clinical trials are required.
This is a major and expensive problem in antiviral drug development, accentuated by the focus of established public health response policies on vaccines and antibodies. Vaccines and antibodies are highly specific to the virus, and even that target virus escapes them readily in the field by acquiring genomic changes.
Thus treatments for the Ebola BDBV virus infection and disease is an important current unmet need.
A clinical trial called “PARTNERS” was started as of July 2, 2026 10 to evaluate two drugs that both require delivery by infusion. More than 300 patients have already been enrolled in this trial across four groups, namely (i) Infusion of a monoclonal antibody cocktail, MBP134, (ii) Infusion of Remdesivir, (iii) Infusion of MBP134 plus Infusion of Remdesivir, and (iv) A control group with local standard of care.
Infusions are inherently non-scalable for the extent of the current Ebola outbreak in the resource- poor areas in DRC. Additionally, infusion treatment also increases risks to health care workers such as needle-sticks, as well as due to patient handling and possible blood exposure.
Additionally, a multi-vaccine trial called “Tumaini” (meaning “hope” in Swahili) has started in DRC at the end of October, 2026, according to the WHO. This trial, based on an adaptive, “ring-vaccination” framework, will initially evaluate the Ervebo vaccine previously approved for Ebola Zaire, and thereafter, when new vaccines are ready, include two other vaccines that are Bundibugyo virus specific (unlike Ervebo), one from the University of Oxford, and the other an mRNA-based vaccine from Moderna ( https://www.riotimesonline.com/ebola-tumaini-vaccine-trial-bunia-congo/ ).
Vaccine trials are long and expensive and it is not known whether effectiveness of a vaccine can be established during the current outbreak to affect the trajectory of the outbreak. During COVID-19, vaccines found to be highly effective during clinical trials were readily escaped by the virus leading to proposals of the need for new vaccine development and deployment at six months intervals.
NV-387 is a broad-spectrum antiviral that we believe would not have the problem of virus escape faced by vaccines and antibody drugs, because no matter how much the virus changes, it still requires binding to the cellular attachment factors that NV-387 mimics.
We were encouraged to propose a clinical trial of the broad-spectrum antiviral NV-387 as an Oral Treatment of the Ebola BDBV infection and disease during this epidemic, in spite of not having primary data for NV-387 against any ebolaviruses.
Oral NV-387 was previously compared with intravenously administered Remdesivir in animal model studies of a lethal coronavirus infection when we were developing NV-387 as a treatment for COVID-19. Orally administered NV-387 was found to be superior in extending survival of the lethally infected animals when compared to Remdesivir I.V. in this study. Therefore, the Company believes that NV-387 Oral Gummies drug can be reasonably expected to provide superior activity compared to at least the Remdesivir infusion that is being evaluated in the PARTNERS clinical trial.
During the reported period, we developed a clinical trial protocol for the Phase II clinical trial of NV-387 Oral Gummies as a Treatment for Ebola Virus disease (EVD). In the current epidemic, the disease is more specifically called Bundibugyo Virus Disease (BVD). Very rapidly, we developed a team in DRC for conducting the clinical trial and submitted a clinical trial application for this proposed clinical trial to the DRC regulatory agency ACOREP. On or about August 4, 2026, ACOREP approved our multi-center clinical trial. We established Ebola Treatment Centers (“ETC”s) for the conduct of the clinical trial. We set up a qRT-PCR lab as a central facility for our ETCs in the Ituri province. This enables us to follow the viral load of each recruited patients by analyzing their lab samples in a timely manner.
10 https://www.reuters.com/business/healthcare-pharmaceuticals/trial-bundibugyo-ebola-treatment-starts-drc-who-says-2026-07-02/
28
The Phase II clinical trial of NV-387 Oral Gummies as a Treatment of Ebola began on September 23, 2026. This Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for the Current Bundibugyo Ebolavirus and other Ebola viruses in the Democratic Republic of Congo (“DRC”) is registered in the Pan African Clinical Trials Registry (pactr.samrc.ac.za) database. The unique identification number for this clinical trial is PACTR202608748555077.
NV-387 Oral Gummies is currently the only orally administered drug in clinical trials for Ebola to the best of our knowledge. This is why medical professionals in the field are looking forward to it, and hoping for success.
The disease severity of EVD/BVD is simplistically stratified into (a) a Dry Stage, wherein patient symptoms include fever, aches, pains, and fatigue that can be confused with many other infections; and (b) a Wet Stage, wherein explosive vomiting and diarrhea, the hallmark clinical symptoms, are presented. The Wet Stage may progress to (c) a Critical Stage, which requires intensive care, with a high fatality rate. Unexplained bleeding may occur in the Wet Stage or Critical Stage. The Critical stage is characterized by imminent organ failures and coagulation system dysregulation resulting in loss of ability to stop bleeding. Recovery from Critical Stage can only occur if all of the following are achieved: organ failures are reversed, viral load is reduced to undetectable level, the coagulation system recovers with the buildup of platelets and coagulation factors, and any concomitant bacterial infections are treated effectively. The Dry Stage or the Wet Stage may progress into Recovery Stage if the viral load can be reduced to undetectable level. Even after eliminating the virus, the patient’s recovery is slow. The patient is deemed infectious, i.e., can transmit the viral infection to others from the dry stage until full recovery, although the potential of transmission is practically nil after the viral load becomes undetectable.
Our Phase II clinical trial for Ebola is divided into two parts. The first part, Phase IIA, is designed to evaluate safety and tolerability of the NV-387 Oral Gummies in Ebola patients, and to determine the optimal dosing regimens based on the disease severity. Phase IIA requires approximately 20 patients. The second part, Phase IIB, is designed to evaluate efficacy of specified dosing regimens that are defined based on the data from the Phase IIA part, for the treatment of Ebola patients with different severity levels of disease. If the drug NV-387 is as effective against Ebola as we have seen in animal models against different viruses (we do not have data against Ebola which is a BSL4 virus), then a large effect size differentiating NV-387 treatment group from the optimal standard of care control group can be expected. On this basis, a relatively small patient size of about 60 patients is projected for Phase IIB. If the results are sufficiently strong, it is highly likely that we will be able to obtain regulatory permission to extend the Phase IIB with an enlarged scope into a Phase III towards regulatory approval.
If the effect size is sufficiently large, we may be able to obtain an Emergency Use Authorization to use NV-387 Oral Gummies for the treatment of Ebola patients. If this happens, there could be a major impact on the trajectory of the epidemic.
Thus this clinical trial is designed to obtain regulatory approval, at least as an emergency use approval, and enable treating the Ebola patients with NV-387 within the current epidemic itself.
During the Phase IIA part of the clinical trial, patients in the Dry Stage as well as those in the Wet Stage are eligible for recruitment. Patients with Critical Stage, or with organ failure, are excluded. HIV co-infected patients are also excluded.
In Phase IIA, the patients will be treated in different dosing regimens depending upon disease severity and will be followed for resolution of viral load. NV-387 treatment will be stopped when the viral load becomes undetectable (as specified). The patients will continue to be treated under the optimal standard of care depending upon the clinical symptoms until clinical symptoms are also resolved. Following this, patients will be observed for up to an additional 48 hrs. and then discharged. Therefore, the Phase IIA part is also likely to provide data regarding possible efficacy of the drug NV-387 against the Ebola disease, when compared with patients treated with the optimal standard of care alone that are outside of the clinical trial in Ebola Treatment Centers.
The crude case fatality rate of the BVD has been calculated at approximately 48% by the WHO. This calculation ignores the fact that the patients dying reported today were part of the cases reported several weeks ago, and not part of the cases reported today. Correcting for this time lag yields a Lag-Adjusted-Case-Fatality rate of approximately 67%. In the ETCs in Ituri province, the actual fatality rate of admitted cases is reportedly about 65% to 75% (verbal communication).
Therefore, a significant reduction in enrolled patient fatality rate, if observed during Phase IIA, would be indicative of effectiveness of the drug, although evidentiary declaration of efficacy (or not) can only be made after Phase IIB. Additionally, the time taken to Ebola viral load becoming undetectable is an important indicator of efficacy. Ebola viral load is directly correlated to the disease severity, clinical effects of disease, and mortality.
29
Patient recruitment in this NV-387 Oral Treatment for Ebola Phase IIA part of the clinical trial started on September 23, 2026. The trial is progressing well with incremental recruitment of patients as the clinical team studies both the clinical effects of the BDBV Ebolavirus and the effects of the NV-387 Oral Gummies drug treatment. An interim report is expected at the end of Phase IIA part. We look forward to sharing the data from the interim report.
NV-387 for the Treatment of Measles
The same drug NV-387 was found to be highly active against Measles virus in a humanized mouse model of lethal Measles virus infection.
Measles is re-emerging globally with significant and large outbreaks in the Western world. In the current Bangladesh 2026 outbreak, 1,205 children have died of Measles, with almost 1,000 new suspected cases in just 24 hours, with 216,765 total suspected cases; whereas confirmed child deaths are 104, and confirmed cases are 23,212; as of October 25, 2026. The difference in suspected cases versus confirmed cases is primarily owing to the paucity of testing infrastructure (https://www.tbsnews.net/bangladesh/health/measles-death-toll-reaches-1205-one-more-child-dies-1579351 ). Countries in Europe and Central Asia reported 33,998 measles cases in 2025 – a nearly 75% drop, compared to 127,412 in 2024, according to the WHO (https://www.who.int/europe/news/item/11-02-2026-measles-cases-dropped-in-europe-and-central-asia-in-2025-compared-to-the-previous-year--but-the-risk-of-outbreaks-remains---unicef-and-who ). This indicates the nature of outbreaks occurring in waves. The Mexico Ministry of Health has reported 13,016 confirmed Measles cases in 2026 as of September 2026, and nearly 20,000 since the outbreak began in January 2025 https://outbreaknewstoday.substack.com/p/mexico-measles-cases-top-13000-in ). As of October 22, 2026, 4,588 confirmed Measles (cases were reported in the United States in 2026, up from the 2025 year total of 2,289 confirmed cases, according to the CDC (https://www.cdc.gov/measles/data-research/index.html ). Measles continues to spread primarily in unvaccinated individuals.
Effectively, the US no longer has Measles elimination status, and it has become an endemic disease in the USA. Measles vaccination rates have fallen in various geographic areas well below the 95% vaccination rate required for maintaining “herd immunity” or population immunity, keeping the virus from spreading. Vaccination rates with the Measles vaccine (usually given to children in 2 doses as a component of the triple MMR vaccine) are likely to continue to fall. Additionally, the Measles virus strain now in circulation is substantially different from the vaccine strain(s) that were derived from the 1968 era. While this old vaccine continues to be effective, its effectiveness may have started decreasing with breakthrough infection rates increasing, based on scientific literature11.
A single case of Measles leads to substantial disruption and economic losses. Measles typically affects school age or younger children, and a single case can lead to quarantining of a large portion of the school body and imposition of remote learning. We believe that if NV-387 is approved for Measles, quarantining can be avoided by treating the suspected contacts with small doses of the drug, and the spread can be eliminated by actually treating the patient with the drug, NV-387. We believe that our animal model studies in humanized mice have clearly demonstrated that NV-387 is a viable drug candidate for treatment as well as prophylaxis of Measles.
Although there is an effective vaccine for Measles12, to treat an already infected patient requires a medicine (treatment or drug), not a vaccine. Additionally, a drug given as a prophylactic could substantially eliminate the societal and economic impact associated with isolation of contacts, especially that from the virtual closures and remote education in lieu of classrooms. This is because, even if vaccines are given to contacts, the effect of vaccine in generating protecting antibodies would be apparent only 2-3 weeks after vaccination, and the measles vaccine requires 2 doses separated in time.
11 https://pmc.ncbi.nlm.nih.gov/articles/PMC11209263/.
12 The Measles vaccine, a live attenuated strain developed circa 1968, continues to be in use and remains effective, even as the Measles virus itself has changed significantly. The vaccine was originally found to be 95% protective, which means 5% of the fully vaccinated persons could still get measles, called a “vaccine breakthrough” infection. At least 95% of the population needs to be vaccinated to confer “population immunity” or “herd immunity” which can be roughly defined as blocking person-to-person spread of the virus. This high percentage required is a result of the extremely contagious and persistent nature of the Measles virus. However, immune-compromised subjects do not benefit well from any vaccines. The percentage of such subjects that do not benefit fully from vaccination has been estimated at about 7-10% of the US population, and is rising due to chronic diseases, auto-immunity, inflammation, diabetes, obesity, as well as environmental factors that have led to increase in cancer rates in younger population in the USA. Analysis of post-elimination Measles cases in the USA have led to vaccine breakthrough rates estimated at 11-13% rather than the historically used value of 5% (J. Leung et al. Measles Cases in the US, 2001–2022 • CID 2025;80(3):663–72. https://doi.org/10.1093/cid/ciae470). There is also personal reluctance for the risk that one’s own child may be affected by a major side effect even as documented rates of side effects are small. There are also communities with religious prohibition for using vaccines. Therefore, reaching 95% vaccination rate is becoming an ever distant goal. Thus, there is an urgent need for a Measles drug to treat persons that get sick.
30
There is no approved treatment for Measles, which is contributing to the severe strain on public health resources globally. This is an unmet medical need.
We are planning a Phase II clinical trial of NV-387 for the treatment of Measles. Given the continuing Measles epidemic in Bangladesh, it is highly likely that this country will be the choice for our clinical trial sites, to provide rapid recruitment and results.
We were granted an Orphan Drug Designation (ODD) as well as Rare Pediatric Disease Drug (RPDD) designation for NV-387 as a Treatment for Measles by the US FDA. If the clinical trials result in drug approval, the Company will be eligible for a Priority Review Voucher (PRV). The Company may be able to sell the PRV for as much as $200 Million, based on recent sales, and generate a substantial revenue possibly even prior to significant commercial sales of the drug itself.
NV-387 for the Treatment of Viral Acute Respiratory Infections (Viral ARI), and Severe ARI (Viral SARI)
We believe that as a single drug that can potentially treat almost any acute respiratory viral infection, NV-387 could be as revolutionary an antiviral drug as penicillin was as the anti-bacterial drug, if and when approved after clinical trials. If a patient presents with a suspected bacterial respiratory infection, the physician can immediately prescribe a broad-spectrum antibacterial treatment such as amoxicillin without waiting for test results. In contrast, at present if a patient presents with a suspected viral respiratory infection, there is no treatment available except for influenza and now COVID, only after identification of the viral cause. Even in the case of influenza, the available drugs have limited effectiveness and need to be given within 48 hours of initial symptoms for best efficacy, as per prescribing information and literature. The COVID drug paxlovid has not shown efficacy in healthy adults, and has other limitations regarding eligibility of a patient as per prescribing information and literature.
In contrast, NV-387 could be prescribed to any patient with an acute respiratory viral infections, without further testing and with potentially no limitations on patient population, if approved for such use, assuming successful relevant clinical trials.
NV-387 was already shown to be highly effective in lethal animal models of viral infections for a number of respiratory viruses. Viruses include the “triple-threat” respiratory viral infections of Coronaviruses, RSV, and Influenza viruses; enabling us to envision that NV-387 would be likely effective against almost all respiratory viral infections, based on its design and its observed activity in animal models.
These robust results also provide us with reasonable and rational confidence that NV-387 will be effective against any variant of bird flu H5N1 that may become successful in person-to-person transmission and thereby may cause an endemic or a pandemic. H5N1 is thought to be a single mutation away from acquiring these capabilities required for causing a sustained outbreak. H5N1 resistance to Tamiflu has emerged in the past, and would likely emerge again. Xofluza, a recently approved influenza drug, is readily escaped by Influenza viruses. Rapivab, an injectable drug that is in the same class as Tamiflu, is also escaped by viral mutations.
In contrast, NV-387 poses a very low likelihood of viral escape, if any. Moreover, orally administered NV-387 was substantially superior to these approved drugs in a direct comparison in an animal model of lethal influenza infection.
Phase II Clinical Trial of NV-387 as Treatment of Viral Acute and Severe-Acute Respiratory Infections (V-ARI and V-SARI) in India We are in discussions with experts regarding a Phase II clinical trial for the evaluation of the effectiveness of NV-387 in the treatment of ARI and SARI of Viral origin. We have prepared a preliminary protocol design of a Phase II adaptive clinical trial that is currently undergoing assessments with regulatory experts.
We plan to propose a novel and unique adaptive clinical trial wherein NV-387 would be given as treatment at enrollment based on clinical indication of acute respiratory infection at presentation. Testing for viral and bacterial infections on the pre-treatment samples will be performed to determine the infectious agent. This information will be used in the interpretation of clinical outcomes. A separate arm of Standard-of-Care (SOC) treatment will be followed for comparison to gauge the effect of NV-387 treatment.
The design of NV-387 suggests that it is likely to be active against most, if not all respiratory viral infections.
NV-387 is expected to be active against most if not all Highly Pathogenic Influenza viruses (HPAI) including H5N1 “Bird Flu” (or Avian Flu), and the Company plans to obtain non-dilutive funding to advance this drug for the H5N1 indication such as grants or contracts from government agencies.
31
NV-387, a Single Drug, Meets Many Unmet Medical Needs in Viral Diseases
At present,
| ● | There is no approved drug for RSV, although three different antibodies have been approved for pre-exposure protection of infants from potential risk of RSV infection, and some vaccines have been approved for use in geriatric patients and adults at risk, as well as for pregnant women. While the market size is projected to be exceeding $8 billion or so, the regulatory development timelines are long for RSV pediatric drug development. |
| ● | There is no approved drug for Influenza that can be reliably predicted to be not escaped by the next potential epidemic or pandemic Influenza virus, including H5N1. All approved influenza drugs are known to be readily escaped by Influenza variants. |
| ● | There is no approved drug for Measles. |
| ● | There is no approved drug for Mpox. |
| ● | The Smallpox approved drugs (under FDA Animal Rule) have significant shortcomings, leaving the US practically unprepared for this bioterrorism scenario despite several billions of dollars in development and acquisitions. |
| ● | There are no approved drugs for Ebola and Marburg viruses other than the Ebola Zaire virus. |
| ● | “Disease X”. A previously unknown viral infection can enter humanity from various possible sources, and could lead to a large epidemic because of lack of medical countermeasures. Ebola Bundibugyo in DRC has resulted in such a challenge, not because Ebola virus is unknown, but because the BDBV variant is distinctly different from other Ebola viruses. NV-387 is in a clinical trial for BDBV. If successful, it would be an important point of evidence that NV-387 could potentially be responsive to an unknown viral disease. NV-387 mimics sulfated proteoglycans which are used by over 90% of human pathogenic viruses, and very likely would be the entry points for any novel pathogen, suggesting the possibility that NV-387 could be useful even for such “Disease X” viral outbreaks. |
| ● | The approved drugs for Influenza are unlikely to meet the challenge of an H5N1 or highly pathogenic influenza virus epidemic, especially since the influenza virus changes readily in the field by multiple mechanisms including mutations, recombinations and reassortments. Mutations are small changes in the genomic RNA that are always occurring as the virus makes copies of itself. Recombinations occur when two different genomic strands exchange portions of their sequences generating a mixed or chimeric variant genomic strand. Reassortment is specific to “segmented” viruses such as influenza wherein a new virus particle is assembled by taking the segments of RNA from two (or more) different influenza viruses that have co-infected a cell. Any of these changes can lead to viruses resistant to traditional drugs, vaccines, and antibodies. Pandemic influenza viruses usually are derived from multiple influenza viruses with such swapping or mixing of genetic code and mutations. |
NV-387, based on relevant animal model studies, and based on safety and tolerability observed in a Phase I human clinical trial, can fulfill the glaring gaps in pandemic preparedness for current and emerging threats, as well as for potential bioterrorism threats.
Thus, NV-387, as a single drug, is responding to several unmet medical needs in viral infectious diseases at once.
Possible Rapid Regulatory Paths, Non-Dilutive Funding, and Potential Revenues for NV-387
We believe that a potentially relatively rapid regulatory path for NV-387 would be enabled by any of its indications that are eligible for “Orphan Drug” status in the USA. Generally speaking, an Orphan Drug is a drug for a disease that has less than 200,000 incidence rate annually, or for a specific bio-terrorism agent such as smallpox. Based on our animal model studies to date, we have identified three different treatment indications that are orphan drug indications for NV-387, namely: (i) NV-387 for the treatment of Measles, (ii) NV-387 for the treatment of Mpox, and (iii) NV-387 for the treatment of Smallpox. Orphan Drug Designation for these cases would enable several benefits.
32
On February 3, 2026, the Company filed and the FDA Office of Orphan Drugs received, applications for Orphan Drug Designation (ODD) of three drugs, namely (i) NV-387 for the treatment of Measles, (ii) NV-387 for the treatment of Mpox, and (iii) NV-387 for the treatment of Smallpox. The Company has retained OnlyOrphansCote, LLC, (“OOC”), led by Dr. Timothy Cote, under a Master Services Agreement as of November 25, 2025, for the orphan drug related activities. Dr. Cote previously served as the Director of FDA Office of Orphan Drugs. OOC prepared and filed the ODD applications on behalf of the Company.
On April 27, 2026, the US FDA awarded an Orphan Drug Designation (ODD) for NV-387 as a treatment of Measles, in a rapid turnaround, pursuant to our ODD application in February. This is an important milestone for the Company, and would help us to move the Measles treatment program relatively rapidly with significant FDA assistance in meetings and specific guidance.
In March 2026, we also filed for a Rare Pediatric Disease Drug (“RPDD”), application for NV-387 as a treatment of Measles. The RPDD designation was awarded in May 2026. The Company employed the consultants OnlyOrphansCote, LLC for this filing. The Priority Review Voucher program (PRV) for Rare Pediatric Disease Drugs was re-authorized by the US Congress and signed into Law by the President on February 6, 2026. Under the PRV program, a sponsor that obtains approval of a new drug or biologic to treat a rare pediatric disease can obtain a transferable voucher for priority review of a subsequent application.
A PRV, subsequent to approval of NV-387 for the treatment of Measles, could provide an important and immediate income source for the Company.
To this end, we continuing to seek “Orphan Drug Designation” for remaining two applications for Mpox and Smallpox from the US FDA. The Company plans to take advantage of the increased FDA interactions for filing appropriate Pre-IND applications and IND applications with the US FDA.
Additionally, the annual drug product requirements for these orphan drugs, when approved, can be met by our existing cGMP manufacturing facilities at our main campus in Connecticut. This could enable rapid revenue generation, to the tune of several hundreds of millions of dollars a year, and would make the Company financially self-sufficient.
We believe that our MPox Phase II clinical trial in Democratic Republic of Congo (DRC), if successful, will likely enable a Phase II/III registration clinical trial for NV-387 as a treatment for MPox under the US FDA auspices, which may provide the shortest possible timeline for NV-387 licensure.
Additionally, we anticipate success of this MPox Phase II clinical trial is likely to enable US Government funding from an agency such as Biomedical Advanced Research and Development Agency (BARDA) or the National Institutes of Health (NIH) for further development of the drug NV-387 as a treatment for the bioterrorism agent smallpox which is a closely related virus. Current FDA guidance for Smallpox drug development is based on the “Animal Rule” and does not require human clinical trials (which would be unethical and impossible to conduct), a licensure route that we believe NV-387 would be successful in, based on relevant animal model studies already conducted.
Such licensure, if obtained, could drive acquisition of the drug by the US government, worth hundreds of millions of dollars in revenues, and this could afford the fastest revenue path for the Company. As an example, Tecovirimat (TPOXX) acquisition contracts have been ranging at about $150 million per year.
We believe that non-dilutive funding for development of NV-387 as a drug is likely to become available from US Government agencies for, Smallpox/Mpox as well as Measles.
Given the now-globe-threatening emergency of Ebola in DRC, we plan on opening an IND with the US FDA for NV-387 as a Treatment for Ebola. We believe that preliminary data from our NV-387-Ebola Phase II clinical trial in DRC will help with these efforts. We believe that an IND will enable us to obtain US Government funding for our Ebola/Marburg program. We have already started work on this initiative. However, due to the workload of the clinical trials, we cannot predict a timeline for when we would be able to file a US FDA IND for Ebola.
As stated earlier, we have begun our US FDA engagement for NV-387 in the rare diseases of Measles, Monkeypox, and Smallpox, with appropriate drug designation applications (ODD and RPDD).
33
Now that Measles ODD and RPDD approved, we plan to follow up with preliminary FDA meetings for guidance, as appropriate. These include certain exploratory meetings and pre-IND meetings.
We believe that the ODD’s will provide several benefits that would accelerate the NV-387 program towards regulatory licensure. These include frequent FDA meetings and rapid decision-making. Additionally, the economic benefits include certain tax credits for R&D costs, waiver of certain PDUFA fees, and a seven year exclusivity for marketing the drug for the licensed indication.
We plan on following up with further US FDA engagements, after future ODD grants, by filing pre-IND applications.
We also plan to seek a Pediatric Investigation Plan (“PIP”) Meeting with the US FDA at an appropriate time, particularly since Measles generally affects mostly children, Mpox Clade I has affected children more so than in prior Mpox outbreaks. Ebola in DRC is causing disproportionately greater mortality in children. RSV, another indication of NV-387, primarily affects neonates, infants and very young children. To this end, we performed a mouse pups safety tolerability, and toxicity study and analyzed the data during the reported quarter. NV-387 demonstrated excellent results as described earlier, enabling the path towards inclusion of pediatric cohorts in clinical trials.
We believe that the pre-IND Meeting for NV-387 for the Treatment and Prophylaxis of MPox will enable us to file an IND for a Phase II/III registrational clinical trial for licensure of the drug for MPox. We plan on leveraging the MPox Phase II clinical trial for this purpose.
We believe that the pre-IND Meeting for NV-387 for the Treatment and Prophylaxis of Smallpox will enable us to file an IND for a Phase II/III registrational clinical trial for licensure of the drug for Smallpox. We may be able to leverage the MPox Phase II clinical trial data as one of the model studies emulating smallpox infection.
We believe that the planned Phase II Viral ARI/SARI Clinical Trial will provide us with substantial actionable data on the safety and effectiveness of NV-387 in treating at least Influenza, RSV, COVID, and provide further information in the utility of NV-387 against many other respiratory viruses including hMPV, Enteroviruses, Adenoviruses, Rhinoviruses, etc.
We plan on being able to initiate an IND under the US FDA for use of NV-387 as the treatment of RSV in pediatric patients, based on the Phase II Viral ARI datasets.
NV-HHV-1 and the HerpeCide™ Program
In addition to NV-387, the Company has previously developed a clinical drug candidate, NV-HHV-1 formulated as skin cream, for the treatment of Shingles. The Company plans to progress NV-HHV-1 into human clinical trials, and further develop the HerpeCideTM program after the Phase II clinical trial of NV-387 for MPox, Measles, ARI/SARI, RSV, and possibly for multiple other indications, including Influenzas.
In the HerpeCide program alone, the Company has drug candidates against at least five indications at different stages of development. The Company’s drug candidates against HSV-1 “cold sores” and HSV-2 “genital herpes” are in advanced pre-clinical studies and are expected to follow the shingles drug candidate into human clinical trials. In addition, the Company has drug candidates against HIV/AIDS, Dengue, Ebola/Marburg, and other viruses.
Intellectual Property
The Company’s drugs are based on several patents, patent applications, provisional patent applications, and other proprietary intellectual property held by TheraCour Pharma, Inc. (“TheraCour”), a related party substantially owned by Dr. Anil Diwan, to which the Company has broad, exclusive licenses. The licenses are to entire fields and not limited to specific compounds. In all, the Company has exclusive, worldwide licenses for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Herpes Simplex Virus (HSV-1 and HSV-2), Influenza and Asian Bird Flu Virus, Dengue viruses, Ebola/Marburg viruses, Japanese Encephalitis virus, viruses causing viral Conjunctivitis (a disease of the eye) and Ocular Herpes (restated), Varicella Zoster Virus (“VZV”) infections (i.e. Shingles and Chickenpox), and SARS-CoV-2 infections. Additionally, the Company has signed a Memorandum of Understanding (“MoU”) on September 23, 2024 to codify the process for all antivirals drug development with TheraCour. Despite the name (“MoU”), this is a legal agreement between the Parties that has formally assigned a right of first refusal (ROFR) for all antiviral drug developments from TheraCour to the Company.
34
This MoU expands the Company’s abilities to opportunistically and rapidly develop novel drugs to treat viral infections of public health importance, even for those viruses that do not exist today and cannot be predicted. The MoU has also formalized the process of development of drugs for unlicensed viral indications leading later to appropriate license agreements. There was no compensation paid to or due to TheraCour as a result of this MoU. The Parties have also agreed in this MoU that any cash milestone payments related to development activities, that are awardable, will become payable only upon the Company having sufficient revenue, thus extending the provisions previously incorporated in the Amendment to the COVID License Agreement, to all present and future license agreements.
In all cases, the discovery of ligands and polymer materials as well as formulations, the chemistry and chemical characterization, and the process development and related work will be performed by TheraCour, a related party substantially owned by Dr. Anil Diwan, under the same compensation terms as prior agreements between the parties, with no duplication of costs allowed. Upon commercialization, NanoViricides will pay 15% of net sales to TheraCour. Milestone payments were made or are specified in certain of the license agreements, details of which have been disclosed at the time the agreements were entered into. The Company negotiates and licenses specific verticals of therapeutic applications from TheraCour if promising drug candidates are found in early research and development against a virus target. TheraCour has not denied any such licenses when requested.
The Company has out-licensed NV-CoV-2 and NV-CoV-2-R for further clinical drug development and commercialization in the territory of India to KMPL, a company of which Dr. Anil Diwan is a passive investor and advisor. KMPL has sponsored the NV-CoV-2 (NV-387) into Phase Ia/Ib human clinical trial, to study the safety and tolerability of the NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies formulations of the API NV-387 in healthy human subjects, described earlier. The clinical trial drug products, NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, were manufactured at the Company’s Shelton campus. Under the agreement with KMPL, the Company will pay for the expenses of the clinical trials, and in return will benefit from having the data and reports made available for regulatory filings in other territories of the world. Upon commercialization, the Company will receive from KMPL a royalty of 70% calculated as the percentage of final invoiced sales less the cost of sales and goods sold to unaffiliated third parties.
NanoViricides Further Technology Developments Curing Virus Infections and Business Strategy
In addition, with the goal of curing virus infections, we have developed novel platform technologies. Under these technologies, we have developed several additional drug candidates that are at different preclinical drug development stages in our pipeline.
Thus, we have developed a strong pipeline of drug candidates that, we anticipate, will yield new drug candidates over a very long timeframe into the future, and, we expect, will enable cures of many currently non-curable viral diseases.
The drug development process is long and expensive. We do not have any approved drugs on the market as of now. We have no customers, products or revenues to date, and may never achieve revenues or profitable operations. We continue to add to our existing portfolio of products through our robust internal discovery and clinical development programs.
We believe we have developed several assets worthy of partnering for further regulatory development and commercialization. We seek to partner and out-license our drug candidates for these purposes. Such partnering may potentially involve initial license fees, milestone payments, and royalty payments to us that could result in an early revenue stream prior to commercial product sales.
We plan to seek non-dilutive grant and contracts funding for our drug candidates that are responsive to bio-defense and pandemic-preparedness objectives, as well as objectives of importance to the health agencies such as RSV and Measles.
There is no guarantee that we will be successful in partnering our drug candidates or obtaining non-dilutive funding for furtherance of our drug development programs. To date, we have financed our drug development programs using equity-based financing from the sale of our shares in private and public transactions including registered direct offerings as well as “At the Market” (ATM) offerings.
NV-387, a First-of-a-Kind, Novel, Ultra-Broad-Spectrum Antiviral Nanomedicine
NV-387 was designed to be and has been found to be an ultra-broad-spectrum antiviral, reminiscent of antibiotics. So far it has been evaluated for antiviral activity in animal models of Coronavirus, RSV, Smallpox, and Influenza infections. In all cases the studies demonstrated extremely positive results for NV-387 treatment that matched or exceeded corresponding available therapeutics or positive controls.
35
1. Coronaviruses: NV-387 was found to effectively reduce the cytopathic effects caused by coronaviruses in cell culture studies without cellular toxicity. It was also found to suppress infection of cells by SARS-CoV-2 pseudovirion as much as a control antibody. NV-387 was found to significantly increase the lifespan of rats infected lethally into the lungs with the coronavirus hCoV-NL63, a model virus stand-in for SARS-CoV-2. Further, the increase in lifespan upon NV-387 Intravenous (“IV”) administration was substantially greater than that obtained with remdesivir IV administration. Additionally, NV-387 given orally also increased the lifespan by more than that seen with remdesivir IV administration.
2. RSV: Oral dosing with NV-387 led to full survival of mice lethally infected with RSV/A2 to cause severe lung disease, whereas the only available drug against RSV, namely ribavirin, showed a limited increase in lifespan. The lethally RSV-infected animals in the NV-387-treated group showed no lung damage in lung histo-pathology study at all time points during the study, whereas animals in the ribavirin-treated group showed progressive pathology. There is no approved drug for the treatment of RSV infection, other than the last resort drug, ribavirin that has limited effectiveness.
Survival Lifespan of Lethally Infected Mice - Lung Infection with RSV A2 | |||||
|---|---|---|---|---|---|
Treatment | Survival, Days | Increase in Survival, | Increase in Survival, | ||
NV-387, Oral | 22+ (Complete) | > | 14 | > | 175 |
Ribavirin, Oral | 14 | | 6 | | 75 |
Vehicle | 8 | | 0 | | 0 |
3. Smallpox/MPox: Oral dosing with NV-387 led to an increase in lifespan of mice lethally infected with ectromelia virus (a cousin and model stand-in for smallpox/MPox viruses) into lungs that was comparable to treatment with tecovirimat (TPOXX®, SIGA). In addition, we also found that in a lethal intradigital footpad infection of mice with ectromelia virus, oral NV-387 treatment led to lifespan improvement comparable to oral tecovirimat treatment. This model is relevant to the skin-abrasion mode of MPox transmission that was found to be dominant in the recent MPox pandemic, and is also found to be operative in the current Congo MPox epidemic. Tecovirimat, approved for Smallpox treatment under the FDA “Animal Rule”, is currently stockpiled under the US Strategic National Stockpile.
4. Influenza: Oral dosing with NV-387 led to a substantially increased lifespan of mice lethally infected with Influenza A/H3N2 compared to the increase in lifespan afforded by treatment with oseltamivir (Tamiflu®, Roche), peramivir (Biocryst), or baloxavir (Xofluza®, Shionogi, Roche), approved drugs against influenza viruses.
Survival Lifespan of Lethally Infected Mice - Lung Infection with Ectromelia Virus | |||
|---|---|---|---|
Treatment | Survival, Days | Increase in Survival, | Increase in Survival, |
NV-387, Oral | 15 | 7 | 88% |
Tecovirimat, Oral | 16 | 8 | 100% |
NV-387 + Tecovirimat, Oral | 19 | 11 | 138% |
Vehicle | 8 | 0 | 0% |
36
NV-387 treated animals showed significant reduction in immune infiltration into lungs. Killer immune cells that migrate in response to infection can kill lung epithelial cells leading to lung damage. Lung mucus index was also significantly reduced upon NV-387 treatment. These effects indicate that NV-387 is beneficial in reducing lung disease pathology.
NV-387 Treatment Significantly Protected Lungs of Balb-c Mice | ||
|---|---|---|
Treatment | Lung Mucus Index | % Immune Cell Infiltration |
NV-387, Intravenous | 32 | 22% |
NV-387, Oral | 53 | 31% |
Untreated Infected Control | 138 | 68% |
Knowing the broad-spectrum nature of NV-387, we anticipate that NV-387 would possess clinically relevant antiviral activity against the HPAI (Highly Pathogenic Avian Influenza) viruses including H5N1 “Bird Flu”.
We note that all three approved influenza drugs oseltamivir, peramivir and baloxavir are known to be prone to viral escape by mutations. In contrast, NV-387 as a host-mimetic is highly unlikely to be escaped by the susceptible viruses.
Oseltamivir-resistant mutants are known and have spread across the world. Resistance to oseltamivir also generates resistance to peramivir because the two drugs share the same mechanism of action. Baloxavir clinical trial demonstrated generation of resistant influenza viruses in 2.2% of treated patients. Thus, an escape-resistant drug that we believe NV-387 is, is sorely needed in the face of potential prospects of a resistant bird flu or influenza epidemic.
Given that, in each of these studies, we have compared the results of treatment with NV-387 with those of approved drugs, and found NV-387 treatment to be superior. We believe that NV-387 has strong prospects for regulatory approval in each of these indications.
5. Measles:
NV-387 was found to have direct antiviral effects against Measles virus in standard cell culture-based testing that measured increase in the extent of surviving infected cells upon treatment with the drug (i.e. “CPE” or Cytopathic Effects Assay).
Additionally, in a lethal Measles infection humanized animal model, NV-387 treatment led to a substantial increase in the number of survival days, to 17 days in NV-387-treated animals, from only 7.4 days in untreated animals, an increase of 130%, in a lethal lung infection of humanized mice by Measles virus.
Humanized mice were required for the animal model because Measles virus only infects humans, and specifically uses hSLAM as the cognate receptor for cell entry, while using the ubiquitous HSPG for congregation next to cells. The mice had human hSLAM (aka hCD150) gene knocked-in, and also had their interferon responses deleted (hSLAM+k.i., IfnAR-/- transgenic mice on C57BL/6 Background). NV-387 mimics the portions on HSPG that viruses bind to, including the Measles virus, and thereby is designed to attack and engulf the virus particle via lipid-lipid mixing and destroying the virus particle’s ability to infect cells
37
The increased survival was correlated with several improvements in the animal health indicating control of viral infection:
✓Slow disease progression, and mild to moderate levels of lung damage as observed in microscopic histopathology.
✓Protection of lungs was also evident from the significant reduction in the level of lung plaques (damage to lung tissue) compared to untreated cases.
✓Reduction in the level of lung-damaging lymphocytes and neutrophils attracted into the lungs (i.e. infiltration) was observed upon NV-387 treatment.
We have thus found that NV-387 has dual benefits of (i) directly reducing the virus itself, together with (ii) protecting systemic cellular damage, and in particular, protecting lungs from viral damage as well as self-inflicted damage from killer cells.
These benefits make NV-387 an unusual and highly desirable antiviral drug.
Novel Orthogonal Nanoviricide Mechanism Has Many Benefits
Additionally, the NV-387 putative mechanism of action is orthogonal and complementary to that of the existing therapeutics, enabling combination therapy with the existing drugs in the market. NV-387 acts on the free virus outside cells blocking infection of new cells by destroying the virus. Existing antiviral therapeutics (except antibodies and entry inhibitors) act on the replication cycle of the virus (ex.: remdesivir, acyclovir, ribavirin, cidofovir, brincidofovir) inside cells, or exiting of the virus (ex.: oseltamivir, peramivir, tecovirimat) from inside cells. Thus combining the action outside the cells of NV-387 with the action inside the cells (or at exit) of these existing agents is expected to lead to complete blockage of any virus thus resulting in a rapid and complete cure. Combining multiple drugs also leads to reduction in emergence of viral resistance, as has been scientifically proven already.
Nanoviricides Can Encapsulate Small Chemicals as Guests, Enabling Improved Pharmacokinetics and thus Activity of the Guest 13
Further, NV-387 also acts as a unique and novel drug delivery vehicle, similar in action to exosomes. Thus, encapsulation of remdesivir in NV-387 enabled oral delivery of NV-387 and the activity of the resulting drug, NV-387-g-Rp, given orally in lethally infected animals, was found to be superior to that of each of NV-387 and remdesivir (Veklury®, Gilead).
We have also developed our own, patent-pending replication inhibitor antiviral agents that can be encapsulated in NV-387 for improved antiviral activity in animal models, with the objective of curing long-term (long COVID) and lifelong (HSV-1, HSV-2, VZV, others) viral infections.
13 A Note on Nomenclature of NanoViricides Candidates:
“g” denotes that the next component is encapsulated as a guest within the preceding nanoviricide. Thus NV-387-g-R refers to remdesivir encapsulated as a guest within NV-387. Similarly NV-387-g-Rp refers to a pro-drug of remdesivir (denoted Rp) is encapsulated as a guest within NV-387. “m” denotes that the next component is mixed in with the preceding nanoviricide. Thus NV-387-m-T refers to NV-387 and Tecovirimat mixed together in a formulation method.
38
Multiple Formulations Enable Treatment of All Segments of Patient Population with Varying Disease Severity, from Mild to Moderate to Severe and Hospitalized
We have successfully developed NV-387 formulations for different severities of viral diseases, and with different patient populations in mind. These include:
(i) | Oral “Gummies” for adults and older children. Oral gummies have an advantage over tablets in that the drug dissolves slowly in the mouth and does not require swallowing. Older adults as well as children with certain respiratory infections are known to have difficulty swallowing. |
(ii) | Oral Syrup. In infants and younger children, the drug must be “titrated” on the basis of body weight or a similar parameter. A syrup form is best suited for this purpose. |
(iii) | Solution for Injection, Infusion or Inhalation. For hospitalized patients with severe disease, injections and infusions are better suited to provide immediate antiviral action. A simple inhalation of the same solution using a standard available nebulizer enables direct delivery to lower respiratory system where the virus is causing lung damage that can lead to lung failure and potentially death. |
Unique, Novel Design Leading to Broad-Spectrum Activity of NV-387
NV-387 has such broad-spectrum activity because it is designed to mimic the attachment receptors to which viruses bind before infecting a cell. The family of attachment receptors mimicked by NV-387 is called Sulfated Proteoglycans (S-PG). This family includes glycosaminoglycans (“GAG”s), and proteoglycans containing heparan sulfate (HSPG), dermatan sulfate (DSPG), chondroitin sulfate (CSPG), and keratan sulfate (CSPG), among others.
Over 90% of known pathogenic viruses bind to one or more of these S-PG class attachment receptors. These viruses include Coronaviruses, Paramyxoviruses (RSV - Respiratory Syncytial Virus, and HMPV- human Metapneumovirus), Dengue Viruses, Chikungunya Virus, Herpesviruses, Human Papillomavirus (HPV), HIV, Hendra and Nipah Viruses, Ebola and Marburg Viruses, and Poxviruses, among others (Cagno V, Tseligka ED, Jones ST, Tapparel C. Heparan Sulfate Proteoglycans and Viral Attachment: True Receptors or Adaptation Bias? Viruses. 2019 Jul 1;11(7):596. doi: 10.3390/v11070596. PMID: 31266258; PMCID: PMC6669472). Thus, a large number of virus families use these S-PG family attachment receptors to concentrate next to cells and thereby efficiently infect cells, with different virus families having preferences to one or more of such attachment factors.
Virus Escaping a Nanoviricide Drug is Unlikely
The NanoViricides Platform Technology has an important advantage in that no matter how much a virus changes in the field, it is unlikely to escape the nanoviricide drug, because the nanoviricide drug is designed to mimic the very features that the virus uses to bind to and enter cells. These specific molecular signature features on the cellular side do not change even as the virus mutates, and nanoviricides are designed to mimic these host-side features. In contrast viruses readily escape antibodies as drugs, as well as vaccine-induced immunity as they evolve in the field, as is well known from the COVID-19 pandemic as well as Influenza pandemics and the continuing HIV/AIDS pandemic.
A safe and effective antiviral drug that the virus would not escape by mutations or field evolution is the holy grail of antiviral drug development. We believe that the NanoViricides Platform technology meets this challenge.
cGMP-Compliant Manufacture of Nanoviricide Drug Candidates in Our Own Facility
NanoViricides is one of a few biopharma companies that has its own cGMP-compliant manufacturing facility. We have designed and developed a cGMP-capable drug substance and drug product manufacturing facility at our headquarters in Shelton, CT. The manufacturing facility comprises a Scale-Up Suite, Clean Room Suites (Class 1000 and Class 100) for Manufacture of the Drug Substances, and Formulation and Packaging Suites for our Drug Products.
We believe our capabilities in manufacturing clinical drug products are now well established. We have manufactured multi-Kg scale clinical supply of drug substances as well as the oral drug products for NV-CoV-2 at our own facility, from synthesis all the way to fill-finish-labeling and packaging, simplifying and expediting the cGMP-compliant manufacturing operations.
39
Our team has successfully and rapidly translated from the research scale production of several grams drug substance to Kg-scale cGMP-compliant manufacture for two different drug candidates, namely NV-HHV-1 and NV-CoV-2, in three different formulations, namely skin cream, oral syrup, and oral gummies, in a very short time span. This includes manufacture of the active ingredients (drug substances), the formulated drug products, and packaged drug products for clinical trials usage.
Manufacturing nanomedicines, especially under cGMP conditions, has been identified as a major risk, and has led to failure of several nanomedicines programs. NanoViricides co-founder Dr. Anil Diwan and our team have employed considerations for cGMP manufacture of our nanomedicines right from the design, development and optimization of the drug candidates, the polymers and ligands that go into them, as well as the processes employed right from the small research scale to the initial process verification batches.
We have thus demonstrated that we have unique expertise in the industry of performing cGMP-compliant manufacture of multiple complex nanomedicine drugs, including cGMP manufacture of (a) drug substance from simple chemical starting materials, (b) the formulated drug product, and (c) the final packaged drug. This is a very significant milestone on the way of NanoViricides becoming a fully integrated pharma company.
We continue to improve the production processes and production scale. Our production capacity is anticipated to be more than sufficient for Phase I, Phase II and Phase III human clinical trials for all of our drugs in development.
We believe that our drug manufacturing capacity is sufficient for initial market entry for any of our immediate clinical targets: Ebola, Mpox, Smallpox, or Measles. The current manufacturing capacity is also sufficient to enable initial market entry of our anti-RSV drug when approved.
Our in-house cGMP production capability has resulted in and is expected to continue to result in significant cost savings across all our drug development programs.
NanoViricides is Fully Equipped for Rapid Antiviral Drug Development from Discovery to cGMP Drug Product Delivery for Clinical Trials; Which Makes NanoViricides a “FIPCO”
In addition to the manufacturing facility, we have on site specialized nanomedicines characterization facility with advanced instrumentation including Wyatt Dynamic Light Scattering instruments, Mass Spectrometry Equipment with “Multiple Reaction Monitoring (MRM)” capability, and others.
We also have on site full-fledged chemistry laboratories to enable drug design, discovery, small scale synthesis, testing, and scale-up of drug candidates worthy of further development.
We also have our own BSL2 Virology Lab for initial evaluation of our drug candidates in cell culture and other in vitro studies.
Thus we are a “Fully-Integrated-Pharmaceutical Company” (FIPCO) unlike most biopharma companies that do not possess the full suite of drug discovery, synthesis, testing, characterization, scale-up, as well as drug substance and drug product manufacture capabilities in house.
Probability of Success in Clinical Trials for Drugs Based on NanoViricides Platform Technology
We are a clinical stage innovative drug development company, advancing from the research and development (“R&D”) stage into regulatory development of our drug candidates towards commercialization. We have been executing rapidly and efficiently, as well as in a cost-effective and productive manner, resulting in successful completion of the Phase I Safety and Tolerability clinical trial of our lead drug candidate, NV-387. We believe that this successful completion with no reported adverse events, which is the most desirable outcome from Phase I clinical trial to establish safety and tolerability of the drug candidate NV-387 is a very important milestone enabling NV-387 to advance for multiple antiviral indications into Phase II efficacy clinical trials. Additionally, this Phase I bodes well for our entire platform technology as being capable of producing drug candidates that are capable of successfully completing Phase I safety and tolerability studies.
40
In addition, our pre-clinical lethal virus infection animal model studies provide us the confidence that the drug candidates we advance into Phase II efficacy clinical trials would have a probability of success. This is because in these animal studies, the animal model plays the role of a “test tube” where the virus can proliferate, and our drugs are designed to directly attack the virus without interfering with functions of the host animal. Additionally, we design the studies to provide clear readout in terms of survival lifespan that can be used for ranking the activity of each tested drug, including already approved drugs where available.
Our non-clinical programs are designed to minimize the risk of failure of our drug candidates in clinical trials. Specifically, we perform evaluation of antiviral activity in lethal studies in direct comparison with known approved drugs if available, and choose drug candidates that show at least comparable or superior activity to the approved ones. We employ lethal infection studies so that the survival time is a clear indicator of the antiviral activity, and can be used to rank relative activity of drug candidates. We believe our success rate of drug approval may be substantially better than industry averages because of the features of our nanoviricides platform technology and the de-risking strategies we employ in drug development.
The NanoViricides Platform Technology: (i) Solving the Problem of Drug Escape by Virus Variants
We believe that our platform technology enables development of drugs that viruses would not escape from. In fact, during the pre-clinical development in the COVID program, we have successfully screened our drug candidates to be able to protect cells against infection by distinctly different coronaviruses. This broad-spectrum, pan-coronavirus drug development approach was adopted to ensure that our drug candidates should remain effective even as variants of SARS-CoV-2 continue to evolve in the field, just as we had already anticipated at the very beginning of the pandemic.
Our nanoviricides™ platform technology is based on biomimetic engineering that copies the features of the human cellular receptor of the virus. No matter how much the virus mutates, all virus variants bind to the same receptor in the same fashion. Thus, our platform technology is inherently designed to combat the issue of viruses escaping drugs by generation of variants.
We mimic the feature on the cellular protein at which the virus binds, and, using molecular modeling, design small molecules that act as “ligands” to bind to the virus surface glycoproteins as though the virus was binding to that cellular protein itself. This host-side chemical signature that the virus uses for infecting cells does not change even as the virus mutates, evolves and generates variants. We chemically synthesize the optimal ligands, and separately attach them to the polymeric micelle scaffold to generate a number of initial “nanoviricide” drug candidates to screen against the virus. Thus the nanoviricide is designed to “look like” the cell membrane with copious amounts of sites for the virus to bind to. When initial interaction of a few ligands with the virus particle takes place, the “metstable” nanoviricide micelle is anticipated to shift its shape, inverting itself onto the virus particle promoted by the “lipid-lipid mixing effect” driven by the lipid chains normally on the interior of a nanoviricide micelle and the lipid membrane that is on the virus surface. Such an attack on the virus particle is expected to de-stabilize the virus particle and uproot the surface glycoproteins it uses for fusing with a cell. Thus the virus would no longer be capable of infecting a cell. This process would result in complete blockage of the “Re-Infection Cycle” of the virus if successful. We call this mechanism “Re-Infection Inhibition”. This mechanism goes beyond the simple neutralization of the virus by antibodies, which requires the human immune system to further take care of the resulting virus-antibody complex. This mechanism also goes beyond the simple blocking of virus entry by small chemical entry inhibitors, which would require extremely high concentrations of the inhibitor to effect complete blockage of each virus particle based on mass-action considerations.
The nanoviricide polymeric micelle is expected to be able to completely coat the virus particle. This is unlike the antiviral antibodies as well as small molecule entry inhibitors that can only partially block the virus particle whereby the virus would still remain capable of infecting a cell. Additionally, antibodies only tag the virus for recognition by the patient’s immune system for clearance. In contrast, a nanoviricide is designed to complete the task of dismantling the machinery of the virus that enables it to infect cells.
Mimicking the attachment receptor families may lead to extremely broad-spectrum drug candidates. We call this implementation NanoViricides Platform Technology Modality #1. NV-387 is an example of this Modality #1, namely, Broad-Spectrum Antiviral Re-infection Inhibitors. NV-387 is designed to mimic key features required by viruses of the host-side sulfated proteoglycans that viruses use as attachment receptors.
Mimicking the cognate receptor would lead to a narrower range but can be anticipated to have greater efficacy compared to mimicking the attachment receptor families. We call mimicking the cognate receptor the NanoViricides Platform Technology Modality #2, or Specific Antiviral Re-Infection Inhibitors.
41
The NanoViricides Platform Technology: (ii) Promising Potential Cures for Infections by Non-latency Viruses
Additionally, we are the only company that, to the best of our knowledge, is developing antiviral treatments that are designed to (a) directly attack the virus and disable it from infecting human cells (i.e. block the “Re-Infection Cycle”), and (b) simultaneously block the reproduction of the virus that has already gone inside a cell (i.e. block the “Replication Cycle”). Together, this strategy of a two-pronged attack against the virus, both inside the cell and outside the cell, and thus blocking the complete lifecycle of the virus, can be expected to result in a cure for coronaviruses and other viruses that do not become latent. We call this implementation, namely encapsulation of other active ingredients within the polymeric micelle of the virus-targeted nanoviricide (which can be based on either Modality #1 or Modality #2), the NanoViricides Platform Technology Modality #3.
As an example of the Modality #3, we have developed NV-387-g-R, which comprises NV-387 that encapsulates remdesivir, a known broad-spectrum antiviral drug that is already approved for COVID treatment of hospitalized patients. Although approved, the clinical effectiveness of remdesivir is limited by its bodily metabolism. It is well known that this drug is highly active in cell culture studies, but the clinical results do not match the expectations corresponding to its cell culture effectiveness. We developed NV-387-g-R to overcome this issue and we have demonstrated that encapsulation within NV-387 successfully improves the PK/PD (pharmacokinetics and pharmacodynamics) profile of remdesivir. The increased circulating lifetime and also concentration of intact remdesivir should improve its effectiveness. Additionally, NV-387-g-R affords the synergistic effects of attacking the virus lifecycle by two orthogonal mechanisms, going well beyond the effects of remdesivir alone. In NV-387-g-R, one component, NV-387, is designed to block the “Re-Infection Cycle”, and the encapsulated guest component, remdesivir is known to block the “Replication Cycle”. Thus NV-387-g-R is designed to block the entire lifecycle of many viruses, not just coronaviruses.
This total attack on the complete lifecycle of the virus is expected to result in the most effective drug candidates. It is now well accepted that multiple antivirals together produce better effectiveness than single ones individually. Our strategy goes beyond simply a mix of multiple antivirals. Our unique, shape-shifting nanomedicine technology leads to substantial improvement in the pharmacokinetic properties of the guest antiviral drug. We have demonstrated this capability in the case of NV-387-g-R, as discussed above, wherein encapsulation of remdesivir within the polymeric micelles of NV-387 protects the former drug from bodily metabolism in animal studies. This allows higher concentrations of the guest drug to be reached and simultaneously extends the effectiveness time period in comparison to the standard Veklury® (Gilead) formulation. The resulting drug, NV-387-g-R has not only significantly improved characteristics for its remdesivir component, but additionally provides the novel re-infection blocking mechanism of NV-387; together enabling complete block of the viral lifecycle, which would potentially result in a cure. (Chakraborty A, Diwan A, Chiniga V, Arora V, Holkar P, Thakur Y, et al. (2022) Dual effects of NV-CoV-2 biomimetic polymer: An antiviral regimen against COVID-19. PLoS One 17(12): e0278963. https://doi.org/10.1371/journal. pone.0278963.)
The NanoViricides Platform Technology: (iii) Routes of Administration Include Oral Route
It is generally believed that nanomedicines as a class would not have good bio-availability if taken orally. We believe that this biased opinion has unnecessarily resulted in curbing potential innovation to overcome the issue of oral bioavailability.
In fact, we have found in pre-clinical animal studies that NV-387 was highly effective when given orally in combating a lethal lung infections that models the severe SARS-CoV-2 disease as seen with the delta variant. In comparing the effect on combating the infection by oral treatment versus injectable treatment, we believe that the bioavailability of the oral dosage forms is substantially good, and in the range of many approved oral drugs. In addition, the API NV-387 was found to be highly effective when given orally in the case of lethal lung RSV infection animal model, a lethal smallpox-emulating ectromelia footpad infection mouse model, a lethal smallpox-emulating ectromelia lung infection mouse model, as well as a lethal Influenza A/H3N2 lung infection mouse model, further substantiating the oral bio-availability of NV-387.
These findings have enabled us to develop oral formulations of NV-387 for human clinical trials. We have successfully developed orally active formulations of our NV-387 in an oral syrup form, as well as an oral gummies (“Chewable Soft Solids”) form. We believe that for mild to moderate viral infection disease, for pediatric, and for geriatric patients, the oral syrup and gummies forms would be highly advantageous over tablets, capsules, injections, infusions, or lung inhalations.
42
The injectable formulation of NV-387 is expected to be valuable in the treatment of severe cases. Out-patient single dose injection treatment may be feasible if the effectiveness of NV-387 in human clinical trials matches that observed in pre-clinical animal studies. Further, this injectable formulation is designed to be deliverable also as an aerosol by a simple hand-held nebulizer device directly into lungs. Such inhalation, as an aerosol, is expected to provide greater benefits to more severe patients by providing high concentration of the drug locally in the lungs where the RSV, SARS-CoV-2, and Influenza viruses cause the most damage in severe cases. The Solution for Injection, Infusion and Inhalation of NV-387 would also be very important in pediatric as well as hospitalized cases.
We believe that the extremely strong antiviral activity we have observed in cell culture studies and in lethal virus infection animal studies, in comparison to approved drugs is a strong positive indication of clinical success and potential regulatory approval of NV-387 for the different viral infection indications we are seeking.
We believe we have demonstrated that we can rapidly develop different types of formulations for different routes of administration, such as injectable, skin cream, lotion, gel, and even oral, because of the inherent strength of the flexible and tailorable Nanoviricide Platform technology. The technology also enables us to develop nasal sprays and bronchial aerosols. We plan to develop the appropriate formulations as necessary.
Developments During the Reported Period of the three months ended September 30, 2026:
We have focused primarily on preparing the clinical trial site for the Phase II clinical trial of NV-387 for the Treatment of MPox in DRC. We have been involved in clinical trial site selection, and now in the site setup activities. As noted earlier, the change of site to a remote hospital location from the original Kinshasa site, as necessitated by the change in prevalence of cases, has increased our workload for site setup, and has caused some additional delays. The Phase II clinical trial of NV-387 for the Treatment of MPox was initiated at the end of September, 2026.
In July, upon receiving the Ebola Pillar Committee’s approval for our proposal to perform a Phase II clinical trial of NV-387 as a treatment for Ebola in DRC, we rapidly put together a team of experts in DRC and developed a clinical trial protocol for this clinical trial. We submitted the clinical trial application for this Phase II trial to the regulatory agency ACOREP, which was approved very quickly in August, 2026. Subsequently, we set up a qRT-PCR laboratory and Ebola Treatment Centers in the Ituri province for our clinical trial. This clinical trial started on September 23, 2026.
We had previously completed manufacture of the NV-387 drug substance batch for the Phase II MPox clinical trial. As we engaged in this manufacturing batch, we have continued to increase the scale of manufacture of NV-387 in our cGMP-compliant facility, effectively doubling the prior batch size.
We commissioned an additional batch of NV-387 Oral Gummies drug product manufacture
Additionally, we have been engaged in efforts to obtain non-dilutive financings for the various applications of NV-387. This has resulted in a shift in our business plan towards tropical and rare diseases, emerging epidemics in the USA, and potential bioterrorism agents. We believe the new plan we have adopted is likely to result in regulatory licensure of NV-387 much more quickly than the regulatory pathway for a commercially important indication such as RSV or Influenza.
We are now executing substantially with an “Orphan First” focus, while continuing advancement of our non-orphan drug candidates along the way. Thus, we have focused on a Phase II clinical trial of NV-387 for Ebola as well as another one for MPox in DRC. Subsequently, we plan on regulatory advancement of NV-387 as a drug for the treatment of Measles. Along the way, we are also continuing to develop a Phase II clinical trial for the use of NV-387 as a treatment of acute respiratory viral infections.
We have continued our investor awareness efforts. Dr. Diwan, our President and Executive Chairman, was interviewed in a “Fireside Chat” by host Mr. Dave Donlin. This video interview was published by StockInvestor Daily under the IPO-Edge program on June 29, 2026 and is available at https://ipo-edge.com/replay-fireside-chat-with-nanoviricides-president-exec-chairman-anil-r- diwan/ . The video is also available on the Company’s website (nanoviricides.com ). The video provides information on the Company’s technology, how it is differentiated from current approaches, and the current programs.
43
Subsequent to the reporting period, Dr. Diwan presented the Company and current status on October 7, 2026 at NIBA’s 153rd Investment Conference in Fort Lauderdale, Florida (NIBA = National Investment Brokers’ Association).
Research Reports. A Coverage Initiating Research Report on the Company by an Independent Analyst has been published, dated July 6, 2026. The report rated the Company with a rating of “Outperform” and has assigned a target price of $6.00, based on the analyst’s estimates. This research report provides a summary of the Company’s current programs, as well as additional longer term programs. The report was written by Mr. Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc. The report and additional coverage of the Company is available at channelchek.com. The report is also available at the Company’s website, nanoviricides.com. Mr. LeBoyer has also published research notes as updates thereafter. The Company has retained Noble Capital as part of its investor outreach program. No part of the Analyst’s compensation was, is, or will be directly or indirectly related to any specific recommendations or views expressed in the public appearance and/or research report. All views expressed in this report accurately reflect the Analyst’s personal views about the subject securities or issuers. This report is intended to provide general securities advice, and does not purport to make any recommendation that any securities transaction is appropriate for any recipient particular investment objectives, financial situation or particular needs.
Our Campus in Shelton, CT
Our campus at Shelton, CT, is fully operative. With our R&D discovery labs, analytical labs, the bio labs for virology R&D, the process scale-up production facility, and the cGMP-capable manufacturing facility established at our Shelton campus, we are in a strong position to move our drug development programs into the clinic rapidly.
Process Scale-Up Production Capability
The process scale-up area is operational at kilogram to multi-kg scales for different chemical synthesis and processing steps. It comprises reactors and process vessels on chassis or skids, ranging from 250mL to 100L capacities, as needed. Many of the reactors and vessels have been designed by us for specific tasks related to our unique manufacturing processes.
cGMP Production Capability
Our versatile, customizable cGMP-capable manufacturing facility is designed to support the production of multi-kilogram-scale quantities of any of our nanoviricides drugs. In addition, it is designed to support the production of the drug in any formulation such as injectable, oral, skin cream, eye drops, lotions, etc. The production scale is designed so that clinical batches for Phase I, Phase II, and Phase III can be made in this facility. The clean room suite contains areas suitable for the production of sterile injectable drug formulations, which require special considerations.
We also have a manufacturing suite for cGMP-compliant Oral Drug Product Formulation, Fill, and Packaging. We manufactured and delivered the clinical NV-387 oral syrup and oral gummies (semi-solids) drug products in this suite using equipment that we had custom-designed and fabricated in the U.S.
We plan to produce multiple batches of a drug product in our facility. At the appropriate time as required we plan to register the facility as a cGMP manufacturing facility with the FDA.
Our BSL-2 Certified Virology Lab
We have significantly enhanced our internal anti-viral cell culture testing capabilities at our Shelton campus. Our Virology Research Lab suite has a BSL-2 (Biological Safety Level 2) certification from the State of Connecticut. This suite comprises three individual virology workrooms, enabling us to work on several different viruses and strains at the same time. This facility is designed only for cell culture studies on viruses, and no animal studies can be conducted at any of our own facilities.
44
We have established several different types of assays for screening of drug candidates against Coronaviruses, SARS-CoV-2 Pseudovirions, VZV, HSV-1, HSV-2, Influenza viruses, RSV, Ectromelia virus (a stand-in for MPox and Smallpox viruses), among others in this lab. We are working on developing an H5N1 Bird Flu pseudovirion assay. We have begun working on the Measles virus during the reported quarter. Our BSL-2 Virological capability has been instrumental in our rapid development of potential drug candidates for further investigation towards human clinical trials. We believe that having developed the internal capabilities for cell culture testing of our ligands and nanoviricides against a variety of viruses has substantially strengthened and accelerated our drug development programs.
NanoViricides Business Strategy in Brief
We intend to perform the regulatory filings and own all the regulatory licenses for the drugs we are currently developing. We will develop these drugs in part via subcontracts to TheraCour, the exclusive source for these nanomaterials. We plan to market these drugs either on our own or in conjunction with marketing partners. We also plan to actively pursue co-development, as well as other licensing agreements with pharmaceutical companies. Such agreements may entail up-front payments, milestone payments, royalties, and/or cost sharing, profit sharing and many other instruments that may bring early revenues. Such licensing and/or co-development agreements may shape the manufacturing and development options that we may pursue. There can be no assurance that we will be able to enter into co-development or other licensing agreements.
We have kept our capital expenditures to a minimum in the past, and we intend to continue to do the same, in order to conserve our cash for drug development purposes, and in order to minimize additional capital requirements.
As a risk factor, we have limited experience with pharmaceutical drug development. Thus, our budget estimates are not based on experience, but rather based on advice given by our associates and consultants. As such these budget estimates may not be accurate. In addition, the actual work to be performed is not known at this time, other than a broad outline, as is normal with any scientific work. As further work is performed, additional work may become necessary or change in plans or workload may occur. Such changes may have an adverse impact on our estimated budget. Such changes may also have an adverse impact on our projected timeline of drug development.
As we develop NV-387 further into Phase II clinical trials, we plan on seeking non-dilutive funding for the Measles, RSV, Smallpox/Mpox, COVID and Long COVID, as well as Influenza and Bird Flu drug development programs as the opportunities arise. We plan on seeking partnerships for all of our drug development programs, as these programs mature further.
We have previously substantially completed IND-enabling studies for a drug candidate for the treatment of shingles rash caused by reactivation of the chickenpox virus (aka varicella-zoster virus, VZV). We plan on undertaking further development of our HerpeCide program into clinical trials after sufficient funding becomes available for re-engaging these programs.
As a risk factor, we recognize that the FDA may require additional studies to be done before approving the IND for any of our programs. Assuming that the FDA and other International regulatory agencies allow us to conduct human clinical studies as we intend to propose, we believe that the coming year’s work plan will lead us to obtain certain information about the safety and efficacy NV-387 in human clinical studies for the treatment of Ebola, MPox. If our studies are not successful, we will have to perform additional clinical trials for NV-387 for other appropriate indications, and/or develop additional drug candidates and perform further studies. If our studies are successful, then we expect to be able to undertake further additional studies as necessary towards drug approval or licensure from regulatory agencies.
Management believes that the Company’s cash and cash equivalents balance of approximately $2.6 million at September 30, 2026, and the Company’s availability, under its $3 million line of credit will be sufficient as well as additional proceeds from At The Market sales of the Company’s common stock will be sufficient to fund the Phase II clinical trial for evaluation of NV-387 for the treatment of Ebola and also for the Phase II clinical trial for MPox in DRC. We plan on seeking additional funding for all of our drug programs from non-dilutive sources as well as raising equity-based financing as appropriate.
As a strategy, we plan to develop the same drug, once initial clinical trials towards a first approval of the drug are completed, for commercial approval for additional indications, such as pediatric applications, special case applications for certain classes of immuno-compromised patients, among others, provided that appropriate levels of funding is available. We believe that adding further indications would significantly expand market penetration and improve return on investment for our drugs.
45
Collaborations, Agreements and Contracts
Karveer Meditech Private Limited, India
On March 27, 2023, we entered into a License Agreement (the “Agreement”) with Karveer Meditech Private Limited, India (“KMPL”), whereby we granted to KMPL a limited, non-transferable, exclusive license for the development and commercialization and further use, sale, or offer of sale of the Licensed Product(s) NV-CoV-2 and NV-CoV-2-R (the “Two Clinical Test Drug Candidates”) in the Territory of India, and as part of the drug evaluation and development, KMPL agreed to sponsor the clinical test drug candidates for Phase I and Phase II clinical trials and act as clinical trials manager. The Company shall have rights to the data generated by KMPL in the clinical trials for use in other jurisdictions, and KMPL shall provide the Company with applicable reports and data. The license conveyed pursuant to the Agreement shall have no set term, and will continue for the period during which KMPL uses the Company’s proprietary technologies. In return, the Company will reimburse KMPL for all direct and indirect costs incurred for the clinical trials, as well as a customary fee of 30% of such costs. Further pursuant to the Agreement, KMPL shall pay the Company 70% of any invoiced commercial net sales of either or both of the Two Clinical Test Drug Candidates to unaffiliated third parties; there will be no minimum royalties, nor any license maintenance fees. KMPL is a related party in that Dr. Anil Diwan, our President, co-founder, and Executive Chairman, is also a co-founder and passive investor without operating control in KMPL.
On June 20, 2024, we had entered into a Master Services Agreement (KMPL-MSA) with KMPL. This MSA enables starting new projects in a specified manner without having to go through a complete agreement process.
The KMPL-MSA enables us to off-load a number of tasks to the KMPL team in India, effectively enabling round-the-clock work capability, and expanding our overall workforce in a cost- and time- efficient manner.
On October 2024, we had authorized KMPL to serve as Project Manager for our Phase II clinical trial of Mpox in DRC under the KMPL-MSA. KMPL brought in Om Sai Clinical Research Pvt. Ltd., India, to serve as CRO for this clinical trial. According to this agreement, we will pay KMPL project management fees of up to 30% over the cost of the clinical trial.
On May 18, 2026, we authorized KMPL to serve as Project Manager for our Phase II clinical trial of Ebola in DRC under the 2024 KMPL-MSA. KMPL brought in Om Sai Research Services, India, to serve as CRO for this clinical trial. According to this agreement, we will pay KMPL project management fees of up to 20% over the cost of the clinical trial. This lower fee was negotiated based on the cost of the clinical trial and the potential workload for the project management.
Om Sai Clinical Research, Private Limited, India
On October 10, 2024, we had signed a clinical trial agreement with Om Sai CRO for the Phase II Mpox clinical trial. The agreement calls for us to pay the costs of the clinical trial, including associated travel related costs for the Om Sai team to travel to and stay in DRC as required. A budget estimate of anticipated activities was included. Any additional necessary activities need to be discussed between the parties, and specifically approved by the Company.
On May 24, 2026, we signed a clinical trial agreement with Om Sai CRO for the Phase II Ebola clinical trial on substantially similar terms as Mpox.
OnlyOrphansCote, LLC, USA
The Company has engaged OnlyOrphansCote, LLC, USA (“OOC-MSA”) to help us with strategy and execution of our orphan drug programs. Dr. Timothy Cote, Principal and Founder of OOC was previously Director of the US FDA Office of Orphan Drugs. OOC helps us with US FDA regulatory strategy as well as Orphan Drug Designation, Rare Pediatric Drug Designation, and other FDA programs, as appropriate.
46
Patents, Proprietary Rights: Intellectual Property – Recent events
NanoViricides’ platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. We intend to obtain a license for poxviruses, enteroviruses, RSV and other viruses that we engage into research for, if the initial research is successful. TheraCour has not denied any licenses requested by us to date. Our business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at the Company’s foundation in 2005.
In September 2021, we entered into a world-wide, exclusive, sub-licensable, license, COVID-19 License Agreement, to use, promote, offer for sale, import, export, sell and distribute drugs that treat COVID-19 infections, using TheraCour’s proprietary as well as patented technology and intellectual property. These licenses are not limited to underlying patents, but also include the know-how, trade secrets, and other important knowledge base that is utilized for developing the drugs and making them successful. In addition, these extremely broad licenses are not limited to some specific chemical structures, but comprise all possible structures that we could deploy against the particular virus, based on these technologies. Further, the licenses are held by NanoViricides for worldwide use. These are described in our most current Annual Report.
COVID Related Drugs: Patent Coverage and Lifetime
Two International PCT patent applications have been filed relating to the application of the TheraCour polymeric micelle technology to drug development for Coronavirus antiviral drugs including ones for the treatment of COVID. PCT/US21/39050 was filed on June 25, 2021. Additionally, PCT/US22/35210 was filed on June 28, 2022, with a request for the same priority date as that of the prior PCT/US21/39050 application. These broad patents cover new compositions of matter, methods of making them (processes), drug formulations, and uses of the articles of manufacture. The patents resulting from these are expected to have expiry dates extending at least into the year 2043, with additional specific extensions possible in various countries based on regulatory extensions for pharmaceutical products. All ensuing patents will be automatically exclusively licensed to NanoViricides for anti-coronavirus drugs pursuant to the COVID-19 License Agreement.
We have licenses to key patents, patent applications and rights to proprietary and patent-pending technologies related to our compounds, products and technologies, but we cannot be certain that issued patents will be enforceable or provide adequate protection or that pending patent applications will result in issued patents.
Table 1: Update on recent Intellectual Property, Patents, and Pending Patents Licensed by the Company
PCT/US21/39050 - SELF-ASSEMBLING AMPHIPHILIC POLYMERS AS ANTI-COVID-19 AGENTS | | Applied: June 25, 2021 | | Ca. 2043 (estimated) | | PCT Application filed. | | TheraCour Pharma, Inc. [Exclusive License]. |
PCT/US22/35210 – SELF-ASSEMBLING AMPHIPHILIC POLYMERS AS ANTI-COVID-19 AGENTS (**) | | Applied: June 28, 2022 | | Ca. 2043 (estimated) | | PCT Application filed, | | TheraCour Pharma, Inc. [Exclusive License]. |
**: The PCT application PCT/US22/35210 was filed with request for priority of PCT/US21/39050. |
47
Analysis of Financial Condition, and Result of Operations
As of September 30, 2026, we had cash and cash equivalents of $2,575,227, prepaid expenses of $405,047 and net property and equipment of $6,275,069. Accounts payable and accrued expenses were $3,150,427, inclusive of accounts payables of $527,657 to third parties, accounts payable to related parties of $704,441 and accrued expenses of $718,934 and accrued expenses-related party of $1,199,395. Stockholders’ equity was $6,412,290 at September 30, 2026. In comparison, as of June 30, 2026, we had $2,794,110 in cash and cash equivalents, prepaid expenses of $368,513 and $6,401,192 of net property and equipment. Our liabilities at June 30, 2026 were $1,190,724 including accounts payable of $323,816 payable to third parties and accounts payable to related parties of $828,577, and accrued expenses of $38,331.
During the three month period ended September 30, 2026, we used approximately $3,641,000 in cash toward operating activities. This was substantially more than the prior year period primarily due to the ongoing expenses of the Mpox Phase II clinical trial and the commencement of the Phase II Ebola clinical trial, both in the DRC.
Research and Development Costs
Direct costs of clinical trials are allocated to the specific drug candidate. We do not maintain separate accounting line items for each project in development. We maintain aggregate expense records for all research and development conducted. Because at this time all of our projects share a common core material, we allocate expenses across all projects at each period-end for purposes of providing accounting basis for each project. Project costs are based upon labor hours performed for each project. Far fewer man-hours are spent on the projects at low priority than the projects at high priority. In the reported quarter, we have focused exclusively on our NV-387 drug development program.
Results of Operations
Revenues The Company is a biopharmaceutical company and did not have any revenue for the three months ended September 30, 2026 and 2025.
Research and Development Expenses – Research and development expenses for the three months ended September 30, 2026 increased $3,704,120 to $4,697,186 from $993,066 for the three months ended September 30, 2025. The increase in research and development expenses for the three months ended September 30, 2026 is due to continuing costs of the Phase II clinical trial for Mpox and costs incurred due to the commencement of the Phase II clinical trial for Ebola, both in the DRC.
General and Administration Expenses – General and administrative expenses for the three months ended September 30, 2026 increased $267,684 to $1,071,303 from $803,619 for the three months ended September 30, 2025. The increase in general and administrative expenses for the three months ended September 30, 2026 is due to an increase in professional fees associated with investor outreach expense. From time to time the Company investor outreach strategies change, with occasional changes in expenditures.
Interest Income – Interest income for the three months ended September 30, 2026 increased $13,926 to $25,553 from $11,627 for the three months ended September 30, 2025. The increase in interest income for the three months ended September 30, 2026 is due to a higher interest bearing balance during the period arising from a capital raise.
Net Loss – For the three months ended September 30, 2026, the Company had a net loss of $(5,742,936) or $(0.23) per share compared to a net loss of $(1,785,058) or $(0.10) per share for the three months ended September 30, 2025. The increase in the net loss for the three months ended September 30, 2026 is generally attributable to the factors discussed above.
48
Liquidity and Capital Resources
The Company’s condensed financial statements have been prepared assuming that it will continue as a going concern, which contemplates continuity of operations, realization of assets and liquidation of liabilities in the normal course of business. As reflected in the condensed financial statements, the Company has an accumulated deficit at September 30, 2026 of approximately $162.8 million and a net loss of approximately $5.7 million and net cash used in operating activities of approximately $3.6 million for the three months then ended. In addition, the Company has not generated any revenues and no revenues are anticipated in the foreseeable future. Since May 2005, the Company has been engaged exclusively in research and development activities focused on developing targeted antiviral drugs. The Company has not yet commenced any product commercialization. Such losses are expected to continue for the foreseeable future and until such time, if ever, as the Company is able to attain sales levels sufficient to support its operations. There can be no assurance that the Company will achieve or maintain profitability in the future. As of September 30, 2026, the Company had available cash and cash equivalents of approximately $2.6 million. The Company’s liabilities at September 30, 2026 were approximately $3.2 million. On July 27, 2026, we raised capital of approximately $3.4 million net of expenses in a Registered Direct Offering of common stock, and pre-funded warrant, and common stock warrants, exercisable into common stock at $1.75. The Company’s existing resources, including availability under its $3 million line of credit will not be sufficient to fund the Company’s planned operations and expenditures for at least 12 months from the date of the filing of this Form 10-Q. As a result substantial doubt exists about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.
The ability of the Company to continue as a going concern is dependent upon controlling its overall expenses and identifying and securing additional financing.
The Company believes that it has several milestones including the anticipated successful completion of Phase II clinical trial of NV-387 as treatment for MPox, and attendant top-line readout, and its recent initiation of Phase II Clinical Trials for treatment of Bundibugyo Ebola Virus. On or about August 4, 2026, the Company received regulatory approval to conduct this clinical trial from Autorité Congolaise de Réglementation Pharmaceutique (“ACOREP”), the pharmaceutical drug regulatory agency of the Democratic Republic of the Congo (“DRC”). The regulatory approval satisfied the conditions perfecting the Company’s financial commitment for the clinical trial. The Company has initiated the Phase IIA part of the trial. The trial is enrolling and is expected to continue to enroll persons exhibiting different disease severity levels.
Additional milestones include successful execution and completion of the Phase II clinical trial of NV-387 Oral Gummies as treatment for Ebola, and for MPox. Our anticipation is based on the known safety of NV-387 in both animal studies and the observations in Phase I human clinical trial, the activity of NV-387 against lethal orthopoxvirus infection in animal models that simulate the dermal transfer of infection as well as direct lung infection, and the broad-spectrum antiviral activity of NV-387 against a number of widely different viruses.
Further, the regulatory timelines for the Ebola, and Mpox and Measles, are likely to be substantially shorter than, say RSV, COVID, or Influenza drug development. This is because in the case of rare and orphan diseases, there are inherent limitations on the clinical trial recruitment due to the small number of available subjects, and the clinical protocols are designed to take this into account. Smaller number of subjects usually makes a clinical trial go faster, except in cases where the incidence rate of the disease cannot support the required recruitment level.
Additional milestones are expected to result from NV-387 regulatory development under the US FDA.
We anticipate opening a US FDA IND for NV-387 as a treatment for Ebola/Marburg (filoviruses).
If NV-387 is successful against Mpox in DRC, then it is likely that we could seek US FDA approval for NV-387 as a treatment for Smallpox, a bio-terrorism agent, under applicable animal rule and with human Mpox study data. Mpox is considered a model virus for Smallpox under the US FDA guidance.
We anticipate filing for and obtaining a preliminary meeting with the US FDA for guidance on developing NV-387 as a treatment for Measles. Thereafter, we anticipate filing appropriate paperwork with the FDA to enable use of NV-387 in Measles patients during the current epidemic in the USA, and filing a pre-IND application to the US FDA for Measles.
The Company then plans to take advantage of the increased FDA interactions for filing appropriate Pre-IND applications and IND applications with the US FDA.
49
The Company has planned a novel Phase II clinical trial for evaluating NV-387 as a first line, empiric therapy for any respiratory viral infection, in an adaptive, basket-style clinical trial design. We are in discussions to execute this clinical trial in India. In a single and relatively low cost clinical trial, we may be able to generate substantial, statistically declarative information, regarding NV-387 as a treatment for (1) Influenza, (2) COVID, (3) RSV, (4) human MetaPneumovirus (hMPV), along with valuable information on effectiveness of NV-387 against many other respiratory infections including Adenoviruses, Enteroviruses, and others, depending upon the rates of incidence in the incoming patients. NV-387 can then progress towards licensure individually against RSV, Influenza, COVID, and other respiratory viruses under the US FDA and internationally.
Additionally, the Company continues toward developing the Pre-IND and IND applications for a Phase IIa clinical trial of NV-387 for the treatment of RSV infection in adults, to be followed by a Phase IIb/III clinical trial of NV-387 for the treatment of RSV infection in hospitalized pediatric patients. To this end, the Company is also evaluating the possibility of a Phase IIa clinical trial of a RSV Infection Challenge in Humans.
The Company executes its plans in a manner consistent with available resources, which can lead to reshuffling of priorities in its programs. Nevertheless, the Company has in the past and will continue to progress towards its goal of revolutionizing antiviral therapeutics.
Management believes that as these various milestones are achieved, the Company would likely experience improvement in the liquidity of the Company’s stock, and such improvement, if any, would enhance the Company’s ability to raise funds on the public markets at terms that may be favorable to the terms offered at present.
Management is actively exploring additional required funding through non-dilutive grants and contracts, partnering, as well as debt or equity financing pursuant to its plan. There is no assurance that we will be successful in obtaining sufficient financing on terms acceptable to us to fund continuing operations.
Management believes that it has on-going access to the capital markets including the “At-The-Market” (ATM) agreement with D. Boral Capital LLC, the Sales Agent.
There can be no assurance that the Company’s plans will not change or that changed circumstances will not result in the depletion of its capital resources more rapidly than it currently anticipates. The Company will need to raise additional capital to fund its long-term operations and research and development plans including human clinical trials for its various drug candidates until it generates revenue that reaches a level sufficient to provide self-sustaining cash flows. There can be no assurance that the Company will be able to raise the necessary capital or that it will be on acceptable terms. The accompanying financial statements do not include any adjustments that may result from the outcome of such unidentified uncertainties.
Off Balance Sheet Arrangements
We have not entered into any off-balance sheet arrangements during the three months ended September 30, 2026.
50
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.
We are a smaller reporting company as defined by 17.C.F.R. and are not required to provide information under this item.
ITEM 4. CONTROLS AND PROCEDURES
Disclosure controls and procedures (as defined in Rules 13a-15 (e) and 15d-15 (e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) are controls and other procedures that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission (the “SEC”). Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in the reports that we file under the Exchange Act is accumulated and communicated to our management, including our chief executive officer and our chief financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. Due to the inherent limitations of control systems, not all misstatements may be detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. Controls and procedures can only provide reasonable, not absolute, assurance that the above objectives have been met.
As of September 30, 2026, an evaluation was carried out under the supervision and with the participation of our management, including our President and our Chief Financial Officer, of the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(f) and Rule 15d-15(f) under the Securities Exchange Act of 1934). Based on this evaluation, our President and our Chief Financial Officer have concluded that the Company’s disclosure controls and procedures are effective as of September 30, 2026.
Management’s Report on Internal Control Over Financial Reporting
Management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rules 13a-15(d) or 15d-15(e) under the Exchange Act. Under the supervision and with the participation of management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness, as of September 30, 2026, of our internal control over financial reporting based on the framework in 2013 Internal Control – Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on our evaluation under this framework, our management concluded that our internal control over financial reporting was effective as of September 30, 2026.
Changes in Internal Control Over Financial Reporting
There were no material changes in our system of internal control over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934) during the three months ended September 30, 2026 that has materially affected, or is likely to materially affect, our internal control over financial reporting.
51
PART II. OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
From time to time, the Company may be a party to legal proceedings in the ordinary course of our business. The Company does not, however, expect such other legal proceedings to have a material adverse effect on our business, financial condition or results of operations.
There are no legal proceedings against the Company to the best of the Company’s knowledge as of the date hereof and to the Company’s knowledge, no action, suit or proceeding has been threatened against the Company.
ITEM 1A. RISK FACTORS
Except as set forth below, there have been no material changes to the risk factors disclosed in Part I, Item 1A, “Risk Factors,” of our Annual Report on Form 10-K for the fiscal year ended June 30, 2026.
Clinical trials are expensive, time-consuming and difficult to design and implement, and their commencement or completion could be delayed, suspended or prevented, which would increase our costs and delay or prevent regulatory approval and commercialization of our drug products.
Human clinical trials are very expensive and difficult to design and implement, in part because they are subject to rigorous regulatory requirements. We estimate that clinical trials for our drug products would take at least several years to complete, and we do not know whether any pre-clinical studies or clinical trials will begin as planned, need to be redesigned or restructured, enroll an adequate number of patients or be completed on schedule, if at all. Failure can occur at any stage, and we could encounter problems that cause us to repeat or abandon clinical trials or product development programs. The commencement or completion of our clinical trials could be substantially delayed or prevented by many factors, including:
| ● | preparing and filing an IND application with the FDA or foreign equivalent, discussions with the FDA or other regulatory authorities regarding the scope or design of our clinical trials, and any delay or failure to obtain regulatory approval or agreement to commence a clinical trial in any country where enrollment is planned, including delays arising from statutory time windows; |
| ● | delays in the submission of reports to, and regulatory acceptance of reports by, the FDA or other regulatory authorities, among others; |
| ● | delay or failure to obtain IRB or ethics committee approval to conduct a clinical trial at a prospective site; |
| ● | the limited number of, and competition for, suitable clinical trial sites, many of which may already be engaged in other clinical trial programs, including some for the same indications as our drug products; |
| ● | delay or failure to reach agreement on acceptable clinical trial agreements or protocols with prospective sites or clinical research organizations (“CROs”), the terms of which can be subject to extensive negotiation and may vary significantly among sites or CROs; |
| ● | inability to obtain sufficient funds required for a clinical trial, or clinical trial costs that are greater than we anticipate; |
| ● | cost escalations in clinical trials, or anticipated costs arising; |
| ● | delay or failure to manufacture or obtain sufficient supplies of our drug products, or other materials necessary to conduct our clinical trials, of adequate quality; |
| ● | determination of dosing; |
52
| ● | slower than expected patient recruitment and enrollment, or higher than expected rates of patient dropout, as discussed further below; |
| ● | unforeseen safety issues, including undesirable side effects or severe or unexpected drug-related adverse effects, including possible deaths, or other unexpected characteristics of our drug products; |
| ● | lack of efficacy during clinical trials, or negative or inconclusive results that lead us, or regulators, to require additional clinical trials or the repetition or termination of clinical trials; |
| ● | inability to monitor patients adequately during or after treatment; |
| ● | inability or unwillingness of patients or clinical investigators to follow our clinical trial protocols; |
| ● | failure of clinical trial sites, CROs or other third-party contractors to comply with regulatory requirements or to meet their contractual obligations to us in a timely manner, or at all, including by deviating from the protocol or dropping out of a study, and our inability to address any such non-compliance or any safety concerns that arise during a clinical trial; |
| ● | clinical holds on, or other regulatory objections to, a new or ongoing clinical trial; and |
| ● | suspension or termination of our clinical trials upon a breach of, or pursuant to the terms of, any agreement with, or for any other reason by, current or future strategic partners that have responsibility for the clinical development of any of our drug products. |
In addition, regulatory requirements, policies and guidelines may change, and we may need to significantly amend clinical trial protocols to reflect these changes, which may require us to renegotiate terms with CROs or resubmit protocols to IRBs for re-examination and may affect the cost, timing or successful completion of a clinical trial. Our clinical trials may be suspended or terminated at any time by the FDA or other regulatory authorities, the IRB or ethics committee overseeing the trial, any of our clinical trial sites with respect to that site, or us, including if it appears that participants are being exposed to unacceptable health risks or if deficiencies are found in our regulatory submissions, our conduct of the trials or our compliance with regulatory requirements.
Our product development costs will increase if we experience delays in testing or obtaining marketing approval. Any failure or significant delay in commencing or completing clinical trials for our drug products would require us to incur additional costs, could prevent or delay regulatory approval and commercialization, and would delay our receipt of any product revenue. Significant delays also could shorten any periods during which we may have the exclusive right to commercialize our drug products, or allow our competitors to bring products to market before we do, any of which could impair our ability to successfully commercialize our drug products and harm our business and results of operations.
We may find it difficult to enroll and retain patients in our clinical trials, which could delay or prevent the start or completion of clinical trials for our drug products.
Identifying and qualifying patients to participate in clinical trials of our drug products is essential to our success. The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the trial until its conclusion, including a number sufficient to ensure adequate statistical power to detect statistically significant treatment effects. Enrollment may be particularly difficult given the limited number of patients who have the diseases for which our drug products are being studied, and the number of patients required may be larger than we anticipate. Many factors may affect our ability to identify, enroll and retain qualified patients, including:
| ● | the patient eligibility and exclusion criteria defined in the protocol; |
| ● | the design of the clinical trial; |
| ● | the size and nature of the patient population and the severity of the disease under investigation; |
| ● | the size of the patient population required for analysis of the trial’s primary endpoints; |
53
| ● | the number and location of participating trial sites, the proximity of patients to trial sites and any limitations on travel or access to trial sites; |
| ● | our ability to recruit clinical trial investigators with appropriate competencies and experience, and the willingness of physicians to participate in our clinical trials; |
| ● | clinicians’ and patients’ perceptions as to the potential advantages and risks of the drug product under study, and of participation in a clinical trial generally, in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating; |
| ● | the availability and efficacy of competing therapies and clinical trials, and the pendency of other trials underway in the same patient population; |
| ● | our ability to obtain and maintain patient consents; and |
| ● | the risk that enrolled patients will drop out of the trials before completion, including for personal reasons. |
Delays or difficulties in enrollment could increase our development costs and delay completion of our clinical trials and associated regulatory submissions, and the timeline for obtaining regulatory approval of our drug products would most likely be delayed.
The design or execution of clinical trials may not support regulatory approval, and regulatory authorities have substantial discretion in the approval process.
The design or execution of a clinical trial can determine whether its results will support regulatory approval, and flaws in the design or execution of a clinical trial may not become apparent until the trial is well advanced. In some instances, there can be significant variability in safety or efficacy results between different trials of the same drug product due to numerous factors, including changes in trial protocols, differences in the size and type of the patient populations, adherence to the dosing regimen and other trial protocols, and the rate of dropout among clinical trial participants. We do not know whether any clinical trials we may conduct will demonstrate consistent or adequate efficacy and safety to obtain regulatory approval to market our drug products.
Further, the FDA and comparable foreign regulatory authorities have substantial discretion in the approval process and in determining when or whether regulatory approval will be obtained for any of our drug products. Our drug products may not be approved even if they achieve their primary endpoints in future clinical trials. These regulatory authorities may disagree with our trial design and our interpretation of data from pre-clinical studies and clinical trials, and may change the requirements for approval of a drug product even after reviewing and providing comments or advice on a clinical trial protocol. Such regulatory authorities may also approve a drug product for fewer or more limited indications than we request, may grant approval contingent on the performance of costly post-marketing clinical trials, or may not approve the labeling claims that we believe would be necessary or desirable for the successful commercialization of our drug products, any of which may have a material adverse effect on our business.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.
For the three months ended September 30, 2026, the Company’s Board of Directors authorized the issuance of 19,384 fully vested shares of the Company’s common stock with a restrictive legend for consulting and legal services. The Company recorded an expense of $27,000 for the three months ended September 30, 2026, which is reflective of the fair value of the common stock on the dates of issuance.
For the three months ended September 30, 2026, the Company’s Board of Directors authorized the issuance of 8,004 fully vested shares of its common stock with a restrictive legend for director services. The Company recorded an expense of $11,250 for the three months ended September 30, 2026, which is reflective of the fair value of the common stock on the dates of issuance.
All of the securities referred to above were issued without registration under the Securities Act of 1933, as amended (the “Securities Act”) in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act as provided in Rule 506(b) of Regulation D promulgated thereunder. None of the foregoing securities as well as common stock issuable upon conversion or exercise of such securities, have been registered under the Securities Act or any other applicable laws and are deemed restricted securities, and unless so registered may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act.
54
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
None.
ITEM 4. MINE SAFETY DISCLOSURES
Not applicable.
ITEM 5. OTHER INFORMATION
(a) None.
(b) Corporate Governance
During the period covered by this Quarterly Report on Form 10-Q, there were no changes to the procedures by which security holders may recommend nominees to the Company’s Board of Directors.
(c) Insider Trading Arrangements and Policies
During the period covered by this Quarterly Report on Form 10-Q, no director or officer of the Company “
55
ITEM 6. EXHIBITS
Exhibit No. | | Description |
|
|
|
31.1 |
| Rule 13(a)-14(a)/15(d)-14(a) Certification of Chief Executive Officer |
|
|
|
31.2 |
| Rule 13(a)-14(a)/15(d)-14(a) Certification of Chief Financial Officer |
|
|
|
32.1 |
| |
|
|
|
32.2 |
| |
|
|
|
101.INS |
| Inline XBRL Instance Document |
|
|
|
101.SCH |
| Inline XBRL Taxonomy Extension Schema Document |
|
|
|
101.CAL |
| Inline XBRL Taxonomy Extension Calculation Linkbase Document |
|
|
|
101.DEF |
| Inline XBRL Taxonomy Extension Definition Linkbase Document |
|
|
|
101.LAB |
| Inline XBRL Taxonomy Extension Label Linkbase Document |
|
|
|
101.PRE |
| Inline XBRL Taxonomy Extension Presentation Linkbase Document |
| | |
104 | | Cover Page Interactive Data File (Embedded within the Inline XBRL document and included in Exhibit) |
56
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| NANOVIRICIDES, INC. | |
|
| |
| /s/ Anil R. Diwan | |
Dated: November 16, 2026 | Name: | Anil R. Diwan |
| Title: | President, Chairman of the Board |
| (Principal Executive Officer) | |
|
| |
| /s/ Meeta Vyas | |
Dated: November 16, 2026 | Name: | Meeta Vyas |
| Title: | Chief Financial Officer |
| (Principal Financial Officer) | |
57